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Abstract 
Tumors shed large numbers of cells into the vasculature. It is supposed that these cells 
give rise to metastases that are the major cause of death from cancer. However, the 
isolation and characterization of the so called circulating tumor cells (CTCs) is still 
challenging since cells are rarely to find among millions of normal leukocytes. The 
objective of this thesis was to characterize colorectal cancer (CRC) - associated CTCs 
and disseminated tumor cells (DTCs) from bone marrow samples. We studied CTC 
incidence in blood samples of CRC patients with the help of the FDA-cleared 
CellSearch
TM
 system. We found that the number of patients with CTCs and the amount 
of CTCs was significantly correlated with the stage of disease. In addition, a significant 
higher rate of patients with CTCs in tumor-draining venous blood compared to the 
central venous blood was found. Furthermore, genomic analyses of single CTCs have 
been performed. This comprised the evaluation of typical CRC-associated mutations 
such as point mutations in TP53, BRAF, KRAS as well as the detection of microsatellite 
instability (MSI). Additionally, some CTCs were used to study global chromosomal 
aberrations by comparative genomic hybridization technique. Results revealed a 
remarkable genomic heterogeneity among the CTCs of single patients. Moreover, we 
detected several cases of genomic disparity among CTCs and the prevailing clone of 
matched cancer tissue. To evaluate differential gene expression that might enable tumor 
cell dissemination, we studied CTCs that were obtained from patients’ blood samples 
and from an othotopic mouse model of metastatic CRC. Gene expression profiles of 
CTCs and cell samples from cancer tissue were compared. The down-regulation of cell 
adhesion molecules such as E-cadherin might be involved in tumor cell dissemination. 
However, a significant epithelial-mesenchymal transition (EMT) in CTCs could not be 
confirmed. DTCs isolated from human bone marrow samples seem to adopt a de-
differentiated phenotype and lack expression of CK20 and CK19. Absence of EGFR 
and the proliferation marker Ki67 confirmed previous reports of dormancy in DTCs.  
With the present work we were able to demonstrate that the molecular characterization 
of single CTCs is feasible. However, further studies are required to increase the 
knowledge about the molecular traits of CTCs which might help to improve therapy 
and prognosis in CRC. 
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Zusammenfassung 
Krebszellen werden von Tumoren zahlreich ins Blut abgegeben. Man vermutet, dass 
diese Zellen Metastasen, die Hauptursache krebsbedingter Todesfälle, initiieren 
können. Jedoch ist die Isolation und Charakterisierung dieser so genannten 
zirkulierenden Tumorzellen (ZTZs) immer noch eine Herausforderung, da sie unter 
Millionen von Leukozyten nur schwer zu detektieren sind. Diese Arbeit wurde mit dem 
Ziel erstellt ZTZs sowie ins Knochenmark disseminierte Tumorzellen (DTZ) im 
kolorektalen Karzinom (KRK) zu charakterisieren. Das Vorkommen von ZTZs in 
Blutproben von KRK Patienten wurde mit dem CellSearch
TM
 System untersucht. 
Sowohl Anzahl der Patienten mit ZTZs als auch Menge von ZTZs korrelierten 
signifikant mit dem Krankheitsstadium. Es fanden sich signifikant mehr Patienten mit 
ZTZs in tumordrainierenden venösem Blut im Vergleich zu zentralvenösem Blut. 
Zusätzlich wurden genomische Einzelzellanalysen an ZTZs durchgeführt. Dies 
umfasste die Analyse von typischen KRK-assoziierten Punktmutationen in TP53, 
KRAS und BRAF sowie das Detektieren von Mikrosatelliteninstabilität. Einige ZTZs 
wurden für die Analyse von chromosomalen Aberrationen mittels CGH untersucht. 
Eine bemerkenswerte genomische Heterogenität innerhalb der ZTZ Populationen 
einzelner Patienten wurde gefunden. Außerdem traten häufig genomische Unterschiede 
zwischen ZTZs und dem dazugehörigen Krebsgewebe auf. Da differenzielle 
Genexpression vermutlich die Dissemination ermöglicht, wurden ZTZs, die aus 
Patientenblut und aus einem orthotopen Metastasierungsmodel in der Maus isoliert 
wurden, analysiert. Die Genexpressionsprofile der ZTZs und Zellproben des Krebs-
gewebes wurden verglichen. Die Runterregulation von Zelladhäsionsmolekülen wie E-
cadherin könnte an der Tumorzelldissemination beteiligt sein. Allerdings konnte eine 
signifikante Epitheliale-Mesenchymale-Transition der ZTZs nicht bestätigt werden. 
DTZs, die aus menschlichen Knochenmarkproben isoliert wurden, scheinen einen 
dedifferenzierten Phänotyp anzunehmen. Die Differenzierungsmarker CK20 und CK19 
wurden nicht detektiert. Berichte über eine niedrige Expression von Ki67 und EGFR, 
die auf eine proliferative Quieszenz in DTZs hindeuten, ließen sich hingegen 
bestätigen. Die vorliegende Arbeit zeigt, dass eine umfassende molekulare 
Charakterisierung von ZTZs und DTZs möglich ist. Um mehr über die molekularen 
Eigenschaften dieser Zellen zu erfahren sind jedoch weitere Studien erforderlich. Diese 
könnten die Therapie und Prognose des KRK verbessern helfen. 
Aim 
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Aim 
The objectives of this thesis were the detection, isolation and characterization of 
colorectal cancer (CRC) - derived circulating and disseminated tumor cells (CTCs 
/DTCs)). To increase our knowledge about the early steps of metastasis we were 
focused on the genomic and transcriptional profiles of CTCs and DTCs. Due to the lack 
of reliable and standardized techniques to isolate and analyze CTCs obtained from 
human blood samples, an efficient CTC isolation protocol had to be designed. 
Transcriptional profiles of solid tumor samples and CTCs had to be ascertained to 
analyze disparities of the mRNA expression profile during and after the dissemination 
process. Additionally, an orthotopic mouse model was established to mimic cancer cell 
dissemination. CTCs that were obtained from the mouse model ought to provide further 
information about the molecular mechanisms involved in tumor cell dissemination. 
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Introduction 
Colorectal cancer 
 
CRC is ranked as the third most common cancer worldwide 
1
. In Europe about 250.000 
new cases of colon cancer are diagnosed each year 
2
. However, the majority of the 
patients does not succumb to the primary tumor but dies due to metastases with a five-
year survival rate of only 30-40% 
3
. Surgery is the primary treatment for CRC; 
nevertheless, CRC seems to be curable only when diagnosed and treated at an early 
stage of disease 
4, 5
. 
CRC progression is mostly staged by the tumor-node-metastasis (TNM) classification. 
This system is based on the depth of invasion of the bowel wall, the extent of lymph 
node involvement, and the presence of distant metastasis. Beyond that, an additional 
system for overall staging was suggested by the Union International contre le Cancer 
(UICC). It is referred as Roman Numeral staging that classifies increased tumor 
progression with roman numerals from 0 – IV (Figure 1) 6. 
 
Figure  1: UICC staging of tumor progression.  
 
CRC development 
 
CRC arises as a result of the progressive accumulation of genetic and epigenetic 
changes within cells from the epithelium lining the colon and rectum 
7
. Usually, CRC 
occurs late in lifetime. 92% of patients are diagnosed after the age of 50 
3
. More than 
80% of CRC cases are regarded as sporadic whereas familial syndromes account for 
about 8-15% of cases 
7
. There are two major forms of hereditary CRC, the familial 
adenomatous polyposis syndrome (FAP) and hereditary nonpolyposis colorectal cancer 
(HNPCC or Lynch Syndrome) 
8
. FAP, a disease in which thousands of polyps develop 
along the colon and harbor the potential to be the founder of a tumor, was traced to a 
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deletion or inactivation of the adenomatous polyposis coli (APC) gene. Its protein 
(APC) plays a major role in the Wnt / β-catenin pathway (Figure 2) 9. If APC function 
is lost, degradation of β-catenin is abolished. B-catenin enriches in the cytosol and 
translocates into the nucleus where it forms a complex with the transcription factor 
TCF/LEF leading to the expression of proto-oncogenes like c-myc or cyclin D1. 
Interestingly, 70 - 80% of sporadic CRC carry inactivating mutations of the APC gene, 
too. CRC with intact APC were often found to harbor activating mutations of β-catenin 
instead 
9
. Thus, the majority of CRC cases are elicited by the aberrant activation of the 
Wnt / β-catenin pathways 10. 
 
 
Figure  2: The Wnt signaling pathway. In the absence of a Wnt signal, the destruction complex 
containing APC and other proteins targets the degradation of cytoplasmic β-catenin in a proteasome-
dependent manner. In the nucleus, Wnt target genes are kept silent by the repressor Groucho interacting 
with DNA-bound T cell factor (TCF). In the presence of a Wnt ligand, the destruction complex is 
inactivated through its phosphorylation dependent recruitment to the Wnt receptor Frizzled (Frz) and its 
co-receptor LRP. Degradation of β-catenin no longer occurs. Cytoplasmic β-catenin translocates to the 
nucleus, where the transcription of multiple genes is initiated through displacement of Groucho and the 
interaction of β-catenin with TCF/ LEF family of transcription factors. Figure taken from Pino and 
Chung 
11
. 
 
Inactivating mutations in various mismatch-repair (MMR) genes lead to the 
aforementioned HNPCC disease or Lynch syndrome respectively. Silenced or 
inactivated MMR genes are found in about 12% of sporadic CRC as well 
12
. They 
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maintain genomic integrity and mediate DNA damage-induced cell death. Loss of 
MMR function can be detected by microsatellite instability (MSI). Microsatellites (MS) 
are short repetitive sequences in DNA that are prone to a higher rate of mutation during 
DNA replication compared to other DNA regions. If MS repeat errors remain unfixed 
due to defects in MMR function, the length of MS can change which might lead to 
frameshift mutations that inactivate or alter tumor suppressor genes such as APC, TP53 
and SMAD4. MS sequences of the TGF-β receptor II (TGFBR2) are particularly 
affected by MSI. Frameshift mutations are found in the TGFBR2 gene in 80% of CRC 
with MSI, leading to alterations in the TGF-β/SMAD signaling 10. TGF-β signaling 
leads to the formation of a hetero-oligomeric complex of SMAD proteins that 
translocates to the nucleus and interacts with key transcription factors (c-jun, 
p300/CBP, c-myc). Moreover, several cell cycle checkpoint genes (p21, p27, p15) were 
found to be TGF-β signaling targets as well. Consequently, defects in TGF-β will 
contribute to loss of cell cycle control 
13,
 
14
. 
The process of colorectal tumorigenesis is complex and involves sequential mutations 
of several key signaling pathways (Figure 3) 
15
. The inactivation of the APC gene is 
believed to be an early event in CRC. Further mutations in oncogenes such as KRAS 
and in tumor suppressor genes like TP53 are required for a complete malignant 
progression. KRAS, a member of the small G-protein family, mediates cellular signal 
transduction and was found to be constitutively active in up to 30-40% of CRC 
patients. 95% of KRAS mutations are found in codons 12, 13 and 61. If KRAS is 
constitutively active, the cellular proliferation is uncoupled from extracellular signals 
such as epidermal growth factors (EGFs) 
16
. TP53 encodes the transcription factor p53 
that is involved in various cellular pathways including cell cycle regulation and 
apoptosis. It is believed that loss of p53 function might allow evasion from cell cycle 
arrest and apoptosis. Inactivating mutations of TP53 often mediate the transition of 
adenomas to invasive cancers 
17
. These mutations are located mainly in the DNA 
binding domain of the p53 protein and are common in about 50% of CRC cases 
18
.  
Furthermore, the PI3K signaling cascade is frequently found to be constitutively active 
in CRC 
19
. This is often caused by mutations in PI3KCA, the gene encoding the 
catalytic subunit of PI3K. One of the most prominent downstream targets of the PI3K 
pathway is Akt. Akt is critically involved in the regulation of apoptosis, gene 
transcription by NF-kB pathway and cell cycle progression 
20
. Interestingly, 
immunohistochemical analyses showed that some tumors expressing high levels of 
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activated Akt are significantly associated with poor prognosis 
21-23
. However, for CRC 
the strong expression of activated Akt was found to be associated with low cancer stage 
and favorable outcome 
24
. 
Beyond genomic mutations increasing data imply that miRNAs are involved in the 
deregulation of CRC associated genes, too 
25
. For instance, a decreased expression of 
miR-34a was found in human colon cancer tissues compared to normal tissues and 
might be linked to a reduced expression of TP53.  
 
 
Figure  3: Multistep genetic model of CRC development. The progression of CRC is accompanied by 
sequential mutational events in key signaling pathways. The activation of the Wnt signaling pathway 
results from mutations in the APC gene and is an early event in tumor initiation. Further cancer 
progression to late adenomas and early carcinomas requires mutations in KRAS and TP53 and loss of 
heterozygosity at chromosome 18q. Aberrant TGF-β signaling and activation of the PI3K/Akt signaling 
pathway through activating mutations in the PIK3CA gene lead to full malignancy. Figure taken from 
Saif and Chu.  
7
.  
 
Metastasis and the epithelial mesenchymal transition (EMT) 
 
Most common tumors, like CRC, are of epithelial origin 
2
. Such carcinomas derive 
from epithelial cells, which are characterized by tight cell–cell interactions, the basal-
apical polarization and the inability to migrate. Genetic damages lead to increased cell 
proliferation and to the formation of an initially benign tumor. Within a multistep 
process neoplastic cells accumulate further genetic and phenotypic changes and switch 
into malignancy. They become invasive, break through the basal lamina, enter the 
lymphatic vessels or penetrate the blood vasculature and reach the circulation. The 
mechanism of how tumor cells can disseminate and spread through the body is 
currently not fully understood. A widely accepted but still controversial discussed 
hypothesis is that tumor cells undergo an epithelial-mesenchymal transition (EMT) 
26, 
27, 28
. EMT is a crucial and highly conserved process in embryo development. It is 
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characterized by the down-regulation of cell adhesion molecules, the loss of a rigid 
cytoskeleton and an increased cell motility which is essential during gastrulation 
movements and neural crest formation. Growth factors including TGF-β, EGF, 
HGF/SF, bFGF and PDGF were found to be initiators of EMT. Diverse signal 
transduction mechanisms mediate EMT, e. g. receptor tyrosine kinases / Ras, Wnt, 
Notch, Hedghog and NFkB pathways 
29
. It has been proposed that invasion and 
metastasis of carcinoma cells is linked to EMT 
30
. This is supported by the finding that 
in most epithelial cancers E-cadherin, a cell-cell adhesion molecule, is inactivated or its 
expression is down-regulated. Various studies have shown that this seems to correlate 
with cancer grade and patient survival 
31-34
. E-cadherin expression can be regulated at 
different levels of gene expression 
35
. A major mechanism, however, is the 
transcriptional repression through the binding of transcriptional repressors to E-boxes 
located at the proximal promoter site. Most prominent transcription factors that down-
regulate E-cadherin expression include Snail, Slug, SIP-1, ZEB1 and TWIST1 
36
. 
Various studies link these transcription factors generally to EMT 
37-40
. For instance, 
Snail was found to down-regulate several epithelial markers such as claudins, 
occludins, desmoplactin and cytokeratins and up-regulate the expression of the 
mesenchymal markers fibronectin and vitronectin. TWIST1 has been associated with 
increased N-cadherin expression which was found to support cell motility.  
In summary, EMT leads to large changes in the gene expression profile and might be 
responsible for loosing cellular assembly. Concomitantly, increased cell motility might 
enable tumor cells undergoing EMT to enter the vasculature and to spread over the 
body (Figure 4). 
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Figure  4: EMT and tumor cell dissemination. Epithelial mesenchymal transition (EMT) seems to be 
critically involved in tumor cell dissemination. Extracellular signaling mediates the up-regulation of 
EMT-inducing transcription factors in the primary tumor. The down-regulation of epithelial markers and 
the up-regulation of mesenchymal proteins facilitate tumor cell migration and invasion into the blood 
vessels.  
 
Dissemination and colonization 
 
Tumor cells that have detached from the primary tumor and circulate in the blood are 
termed CTCs. It is estimated that large numbers of CTCs enter the circulation but only 
a small portion is able to survive and to establish metastasis at secondary organs 
41, 42
. 
The main portion of CTCs can not sustain the shear stress in the blood stream 
43
 and 
undergoes apoptosis. Moreover, for survival CTCs have to develop mechanisms to be 
protected from anoikis, which is a kind of programmed cell death that is induced when 
anchorage-dependent cells detach from the extracellular matrix 
44
. Occasionally 
observed CTC clusters or multicellular tumor cell aggregates 
45
 might be a way to 
protect CTCs from mechanical burdens and anoikis. Furthermore, CTCs need to be 
protected from immunosurveillance. Besides a decreased expression of MHC I 
proteins 
46
 it has been reported that CTCs might avoid NK cell-mediated lysis through 
the aggregation with platelets 
47, 48
. In addition, Pawelek et al. have suggested that 
CTCs might fuse with bone marrow-derived cells (BMDC) in the blood 
49
. The BMDC 
– CTC fusion might increase CTC survival and could provide an explanation for 
acquired mesenchymal traits in CTCs. 
 
Blood vessel 
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Liver metastases are pre-dominantly observed in CRC 
50-52
. CTCs, which are shed from 
the primary tumor, reach the liver through the mesenteric and portal venous system. 
The majority of the CTCs is filtered by the liver before they are able to enter the 
systemic circulation. According to a cascade theory 
50
 of cancer progression that 
suggests the step-wise progression of malignancy, the CTCs that are trapped in the liver 
grow out to metastases and increase the amount of CTCs in the blood. This might 
explain why CTCs in peripheral blood are primarily found in patients with overt 
metastases 
53
. In contrast to that hypothesis it is also conceivable that numerous CTCs 
pass the liver and distribute throughout the body. In this alternative scenario the usually 
observed homing of CTCs to liver or lung would be attributed to adhesion molecules 
and certain cytokines. Already in 1889 Stephen Paget hypothesized that metastasis is 
not a random process and presumed that there must be a strong impact of the 
interaction between tumor cells and the microenvironment 
54
. Paget developed the 
“seed and soil” hypothesis claiming that certain tumor cells (the seed) metastasize to 
certain organs (the soil). It is widely accepted that tumors and CTCs are a very 
heterogeneous cell population. The question which properties of seed and soil 
efficiently support metastasis is still largely unknown. However, the local expression of 
chemoattractants and cell adhesion molecules might explain the organ tropism of 
disseminated cancer cells. It was found that the expression of the chemokine receptor 
CXCR4 on breast cancer cells guides them to tissues with high expression levels of the 
CXCR4 ligand SDF-1. These tissues include bone marrow, liver and lung 
55
. In 
addition, a receptive microenvironment seems to be a prerequisite to successfully 
establish a metastatic lesion at a distant site. It was found that VEGFR-1
+ 
bone marrow-
derived hematopoietic progenitor cells can be mobilized to the invasive front of the 
primary tumor as well as to the designated target organs of metastasis where they 
support angiogenesis and tumor progression 
56
. Already before the arrival of tumor 
cells VEGFR-1
+ 
bone marrow-derived hematopoietic progenitor cells together with 
endothelial and stromal cells prepare the pre-metastatic niche as the future site of 
metastasis through modification of the extracellular matrix and complex chemokine 
signaling. Once, CTCs/DTCs reach the pre-metastatic site, they extravasate from the 
blood vessels and become sessile again. It is supposed that the process of EMT is 
reverted and the epithelial traits need to be re-gained to from metastases 
57
. Probably, 
the DTCs stay initially in a dormant state. Metastatic relapse in patients with CRC can 
occur years after diagnosis and resection of the primary tumor 
58
. Therefore, it is 
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assumed that many cancer patients harbor dormant tumor cells that even resist 
chemotherapy due to their low proliferation rate, appropriate detoxifying enzymes and 
presumable stem cell properties. Currently unknown factors can trigger tumor cell 
proliferation again. In this case the metastatic niche undergoes an angiogenic switch by 
recruiting endothelial progenitor cells. Finally, increasing vascularization enables the 
progressive growth to marcometastases.  
 
Tumor stem cells 
 
Although a tumor develops from a single, mutated cell, tumor cells within a tumor are 
not identical 
59
. One explanation could be the genomic instability of tumor cells 
60
 and a 
constant selective pressure for cells to adapt to the tumor microenvironment. 
Alternatively, it was proposed that a hierarchy exists in tumors with only a minority of 
cells that are capable of regenerating the tumor. These cells are termed cancer stem 
cells 
61
. The bulk of the tumor, however, is formed by cells with a limited capacity to 
divide. Currently it is not clear if tumor stem cells originate from normal stem cells or 
from progenitor cells with a blocked differentiation program or even from 
differentiated cells that somehow acquired self renewing capacity. The hypothesis that 
cancers like all other tissues originate from stem cells is not new and is supported by 
the finding that only a small subpopulation of cancer cells is able to induce tumor 
growth in mouse models. Biomarkers to identify and define cancer stem cells, among 
them CD44, CD133 and CD26, are still not standardized and under intensive 
investigation 
62, 63
. Nevertheless, the cancer stem cell hypothesis is still controversial 
64-
66
. Critics state that it might be an in vitro assay-associated artifact. Supporting 
evidences rely mainly on xenotransplantion studies in immunosuppressed mice. 
Furthermore, they allude that the low numbers of human tumor cells producing tumors 
in mice arise from difficulties of the tumor cells to adapt to the novel and foreign 
microenvironment. Hence, common assays rather select for cells that are tumorigenic in 
mice but neglect that tumor formation depends on complex interactions with 
extracellular matrix components and multiple non-tumor cells that might not be present 
in the xenotropic mouse model. 
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Is metastasis initiated by tumor stem cells? 
 
If tumor stem cells exist, then they might be already present in benign lesions. 
Consequently, additional features have to be acquired to develop malignant growth. An 
intriguing concept of malignant tumor progression was presented by Brabletz and 
colleagues
67
. They propose the existence of a mobile cancer stem cell fraction in 
tumors and metastases they term migrating cancer stem cells (MCS). According to their 
hypothesis, these cells might originate from stationary cancer stem cells that 
additionally gained cellular mobility through transient acquisition of EMT. The concept 
comprises that a migrating front of MCS extends the tumor mass at the tumor-host 
interface and the formation of metastases is caused by long distance migration of MCS. 
 
Cancer progression models 
 
Early or late dissemination of tumor cells 
 
The resection of the primary tumor is often not curative in CRC since tumor cells might 
have already disseminated and are spread throughout the body 
68
. Systemic treatments 
to prevent the formation of distant metastases were developed to target DTCs 
69
. 
However, DTCs are poorly characterized and we know hardly anything about the 
metastatic founder cells so far. From this it follows that predictions about the properties 
of DTCs require at least models of cancer progression. In particular it is important to 
elucidate if primary tumors can be used to predict the success of systemic treatments to 
defeat DTCs (Figure 5). Two basic models of metastasis are discussed 
70
. Basically, 
they are focused on the question if tumor cell dissemination is an early or late event in 
tumor progression. The linear progression model states that cancer cells disseminate 
not until the tumor reaches full malignancy. Consequently, DTCs resemble the primary 
lesion. The second model suggests a parallel progression of DTCs and the primary 
tumor. This means that DTCs leave the primary lesion already at an early point of time. 
In this scenario DTCs develop independently and divergent from the primary tumor. 
There are arguments for both models. The linear progression model is supported by the 
finding that the appearance of metastases correlates with tumor size and that an early 
resection of the primary lesion prevents dissemination of cancer cells and increases the 
patients’ survival. However, the model can not explain the occurrence of metastases in 
early stage cancer or of metastases of unknown primary site. Moreover, based on the 
assumption that primary tumors and metastases have a comparable growth rate, one can 
Introduction 
 
18 
estimate the point of time when a metastasis started to grow. Data from registries, that 
report the time from resection to the appearance of distant metastasis, contradict the 
late dissemination of tumor cells because metastases would be expected to emerge 
much later in time. In addition, genetic evidence favors the parallel progression model. 
Techniques for whole genome analysis of single DTCs revealed that significant fewer 
genetic aberrations can be found in DTCs compared to primary tumor cells indicating 
an early dissemination of tumor cells. Furthermore, genomic disparities in matched 
primary tumors and manifested metastases rather support the parallel progression 
model. 
 
 
Figure  5: Early or late dissemination of cancer cells. A The late dissemination and metastatic cascade 
model predicts that disseminating tumor cells (DTCs) resemble the most aggressive clone and therefore 
the tumor at time of diagnosis. Therapies can be selected on the basis of analysis of the primary tumor. B 
Parallel progression complicates therapy selection. Genomes may vary between different sites and 
undergo independent progression. Specific genetic changes might be selected at different sites and 
different targeting strategies have to be applied for DTC, small clusters and small colonies. Figure and 
description was taken from Klein 
70
. 
 
 
 
A 
B 
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Disseminated tumor cells  
 
Definition 
The term minimal residual disease (MRD) comprises single tumor cells and 
micrometastases throughout the body. According to the location in the body further 
distinctions are required: 
- Disseminated tumor cells (DTCs) comprise tumor cells that are found in lymph 
nodes or in the bone marrow. 
- Circulating tumor cells (CTCs) are located in the blood. 
 
Methods of detection 
Metastatic spread due to tumor cell dissemination is the most threatening aspect of 
cancer. To increase our knowledge about the metastatic process several techniques 
have been developed to capture CTCs in blood and DTCs in bone marrow and lymph 
nodes for enumeration and characterization. The presence of lymph node - associated 
DTCs is usually confirmed immunohistologically by epithelial specific staining, wheras 
diverse techniques for the detection of CTCs and bone marrow-associated DTCs exist. 
Techniques for CTC and DTC detection are highly analog; therefore, this chapter is just 
focused on CTC identification methods. 
Since CTCs are very rare and hard to find in a strong background of leukocytes (often 
less than one in 10
6 
peripheral blood mononucleated cells (PBMC)), sophisticated 
approaches are needed for CTC detection 
71, 72
. Most protocols apply a density gradient 
centrifugation in combination with an immunomagnetic isolation step to enrich CTCs 
from a blood sample. However, CTCs seem to be very heterogeneous in their 
morphology and in the expression of cell-surface antigens which probably leads to a 
bias in all used enrichment methods. Most data were obtained from the CellSearch
TM
 
(Veridex) system 
73
 which represents the only FDA- approved device for CTC 
detection in colorectal, prostate and breast cancers that allows the enumeration of CTCs 
in whole blood specimens of cancer patients. CTCs can be distinguished from 
leukocytes due to the expression of epithelial protein markers which are normally 
absent on blood cells. The purification / detection process starts with the 
immunomagnetical enrichment of EpCAM-expressing CTCs with the aid of an 
EpCAM-conjugated ferrofluid. Afterwards the specimens are stained with a nuclear 
stain to prove cellular integrity and fluorescent antibody conjugates directed against 
CD45, cytokeratin 8, 18 and 19. A trained operator can distinguish cytokeratin-positive 
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CTCs from residual CD45- positive leukocytes to determine the CTC amount in a 
7.5 ml blood sample (Figure 6).  
 
 
Figure  6: The CellSearch. The CellSearch
TM
 system is used for the detection of CTCs. The figure 
summarizes the processing of a blood sample as explained in the text.  
 
Several other techniques for CTC detection have been developed recently. Most of 
them rely on EpCAM and cytokeratin expression of the target cells. For instance, the 
CTC chip is a microfluidic device that captures EpCAM-expressing CTCs within an 
array of antibody coated microposts 
74
. Subsequent cytokeratin staining enables the 
identification of CTCs. EpCAM expression of target cells is also required for the 
automated cell separator MagSweeper
TM
 
75
 that is designed to perform efficient 
immunomagnetic CTC enrichment. Other surface-marker-based CTC detection devices 
include standard flow cytometry and laser scanning cytometric based systems, such as 
Maintrac
TM
, Ikonoskope
TM
 and Ariol
TM
.  
A different approach to isolate CTCs is the ISET system 
76
. Since CTCs usually are 
larger than peripheral blood leukocytes, it is possible to separate them with the ISET 
system by size filtration. However, the method is controversial because the CTC size is 
highly variable and sometimes comparable to leukocytes 
77
.  
Another technique, the EPISPOT (Epithelial immunoSPOT), was designed to detect 
viable CTCs 
78
. Leukocyte-depleted blood or bone marrow specimens, that potentially 
contain CTCs, are cultured to accumulate a sufficient amount of marker proteins. By 
adapting the enzyme linked immunospot technology CTC detection is getting feasible. 
Other techniques use polymerase chain reaction (PCR) based systems. The Adnatest
TM
 
method relies on the immunomagnetic CTC isolation and the subsequent detection of 
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tumor marker expression in a multiplex PCR 
79
. A big drawback of that method is that 
CTCs can not be quantified. The lack of quantification is caused by the impossibility to 
determine from how many cells the detected transcripts are derived.  
In summary, despite several CTC detection methods are available a standardized CTC 
detection system without bias is still lacking. CTCs conserve characteristics of the 
epithelial cancer tissue from which they originate. This is the basis for the common 
detection methods; however, it is also the main point of critics. In the course of EMT 
and the dissemination process CTCs might down-regulate the expression of epithelial 
markers, such as EpCAM, a protein that is also involved in cell adhesion. Standardized 
and more unbiased methods for CTC detection would be favorable to get a 
comprehensive insight in tumor cells shedding.  
 
Clinical significance of CTCs and DTCs in CRC 
 
Routine histopathological methods have confirmed that lymph node involvement is one 
of the most important prognostic factors for colon cancer patients 
80
. However, these 
methods frequently miss smaller lesions and micrometastases. Increasing sensitivity of 
detection due to molecular detection methods revealed that lymphatic spread of tumor 
cells seems to be common already in early stage CRC. Since lymph node - associated 
CTCs are found in N0-staged lymph nodes (analyzed as negative in conventional 
pathology) in up to 86% of cases, it is not clear to what extent micrometastases and 
single lymph node - associated CTCs contribute to a worse prognosis in CRC 
81
 
82
 
83
. 
Numerous studies addressed the question if the detection of CTCs and DTCs are a 
prognostic factor for progression free survival and overall survival in CRC 
84
. Due to an 
increasing amount of data obtained from the CellSearch
TM
 system the case for 
metastatic CRC (mCRC) seems to be quite clear 
85
 
86, 87
. Cohen showed that CTC 
counts above the baseline of 2 CTCs per 7.5 ml of peripheral blood indicate an about 
50% reduced progression free survival and overall survival in mCRC patients 
(Figure 7). 
 
Introduction 
 
22 
  
Figure  7: CTC count and prognosis in mCRC. Progression-free survival (panel A) and overall 
survival (panel B) for metastatic CRC patients by favorable (<3) versus unfavorable (≥3) baseline CTC 
count. Figure was taken from Cohen et al. 
86
 
 
However, the impact of CTCs and DTCs in non-metastasized CRC patients is still 
controversial. The main problem is that the available studies vary dramatically in study 
design and in the applied methods. Standardized guidelines are required to obtain 
comparable study results. 
Only a few studies address the prognostic significance of DTCs in the bone marrow of 
CRC patients 
84
. It is supposed that the bone marrow might serve as a reservoir of 
DTCs and would be a good indicator for MRD. Lifespan of CTCs in the blood is 
short 
88
 and the fact that CTCs can still be found in the blood months after removal of 
the primary tumor, indicates that CTCs might circulate among different metastatic 
sites 
89
. The bone marrow might be a source of CTCs even years after curative 
resection. DTCs usually stay there in dormancy until they are released again due to 
unknown stimuli. Since the available studies are very heterogeneous in sample size, 
staining methods and follow-up-times, further studies are required to finally assess the 
role of DTCs in CRC 
90
. 
 
Molecular characterization of DTCs and CTCs 
 
Understanding the process of metastasis requires the molecular analysis of CTCs and 
DTCs. However, their rareness is the major difficulty for a detailed characterization. 
Fortunately, along with improvements in single cell techniques the characterization of 
the metastases precursor cells is becoming more and more feasible.  
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Immunocytochemistry 
 
The phenotypic heterogeneity of DTCs isolated from bone marrow samples was shown 
by immunocytochemical double or triple stainings 
91
 (Figure 8). DTCs detected in the 
bone marrow are often dormant which was indicated by the low expression of 
proliferation markers such as Ki67, p120 and PCNA. This might explain the 
appearance of clinical metastases late after the curative resection of the primary 
tumor 
58
. With regard to immune escape mechanisms the down-regulation of major 
histocompatibility complexe I (MHC I) was found on DTCs of breast cancer patients 
92
. 
Recent studies also report that the over-expression of Her2, a receptor for EGFR, in 
breast cancer-associated DTCs and CTCs is linked to a poor clinical outcome 
93
. This 
finding might support the use of trastuzumab
TM
, a humanized anti-Her2 monoclonal 
antibody, for systemic treatment in Her2 over-expressing breast cancer patients. 
Furthermore, urokinase-type plasminogen activator receptor (uPar) expression on 
DTCs correlates with metastatic relapse in gastric cancer 
94
. It was speculated that 
signaling mediated by Her2 and uPar might be involved in growth induction in dormant 
DTCs. Since heterogeneity of CTCs and DTCs becomes more and more evident 
45
, the 
search for the metastasis founder cell fraction is proceeding. Based on CD44, CD24 
and ALDH1 the existence of a potential cancer stem cell subpopulation was reported 
for breast cancer-associated CTCs 
95
. However, so far nothing is known about the 
prognostic significance of this finding.  
 
 
Figure  8: Heterogeneity of DTCs. Phenotypic profile of DTCs in bone marrow determined by 
immuno-cytochemical double staining using anti-cytokeratin antibodies for tumor cell detection. Figure 
was taken from Pantel et al. 
91 
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Genomic characterization 
 
The genomic analyses of DTCs and CTCs were initially necessary to confirm the 
malignant origin of cytokeratin-positive stained cells in the bone marrow. By means of 
fluorescence-in-situ-hybridization 
96
 it was possible to show chromosomal aberrations 
in CTCs / DTCs. When later whole genome amplification techniques became available, 
single cell comparative genomic hybridization (CGH) was applied to screen for 
chromosomal gains and losses. It was reported that DTCs generally display fewer 
genetic aberrations than their matched primary tumors in breast, prostate and 
esophageal cancer supporting the theory of an early dissemination of tumor cells 
97
. 
Growing evidence indicates that DTCs might develop independently from the primary 
tumor. This may lead to primary tumors and metastases with different mutations in 
oncogenes or tumor suppressor genes. For instance, disparate KRAS mutations of 
tumors and matched metastases were observed in up to 60 % of CRC 
98
. Since 
constitutively activating KRAS mutations in CRC have been associated with failure of 
anti-EGFR therapy, the molecular profile of CTCs/ DTCs is becoming increasingly 
important to defeat systemic cancer and to predict therapy response 
99
.  
 
Transcriptome analysis 
 
Array-based gene expression analysis could provide crucial information about the 
dissemination and survival mechanisms of CTCs and DTCs and might also permit the 
identification of novel therapeutic targets fighting systemic cancer. However, these 
approaches are mainly limited by the low number of CTCs / DTCs and impurity of the 
applied isolation strategies. Most of the available studies were solely able to perform 
RNA expression analyses of CTC or DTC - enriched cell fractions in a background of 
several thousands of leukocytes 
100-102
. Despite these limitations Watson et al. provided 
supporting evidence for EMT in DTCs by means of global gene expression 
profiling 
102
. They detected the expression of TWIST1, a putative inducer of EMT, in 
DTCs in early stage breast cancer patients and found TWIST1 expression correlated 
with early disease relapse.  
Klein et al. 
103
 reported the transcriptome analysis of single micrometastic cells from 
bone marrow samples. With the help of a sophisticated RNA extraction and subsequent 
cDNA amplification strategy it was possible to compare the gene expression profiles of 
DTCs and to conclude that most of DTCs adapt a dormant cell cycle status. 
Additionally, they detected the expression of EMMPRIN (extracellular matrix 
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metalloproteinase inducer) in the analyzed micrometastatic cells. EMMPRIN is thought 
to facilitate tumor invasion by stimulation of matrix metalloproteinases. 
Immunocytostaining of cytokeratin positive DTCs of diverse cancers revealed 
EMMPRIN expression in 82 % of DTCs indicating their invasive properties. 
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Results 
The objective of this thesis was to characterize CRC-associated CTCs on the 
transcriptional and genomic level. Following the trail of hematogenous tumor cell 
dissemination we recorded the CTC amount and distribution in patients’ blood obtained 
from local tumor draining veins and central veins. CTCs that have been detected were 
isolated for their genomic characterization with regard to point mutations, MSI and 
chromosomal instability. In addition, intact and freshly processed CTC samples were 
required to enable mRNA expression profiling. Therefore, we had to establish a reliable 
CTC enrichment and isolation protocol. Finally, a mouse model of metastatic CRC was 
developed. The CTCs that were obtained from the mouse model ought to provide 
further insights into the dynamic regulation of mRNA expression involved in tumor 
cell dissemination.   
 
Compartmental differences of CTCs in CRC 
 
Due to the clinical significance and prognostic value of CTCs in CRC, we were deeply 
interested if the presence and the detection rate of CTCs differs among different blood 
compartments. For that purpose we used the US Food and Drug Agency (FDA) 
approved CellSearch
TM
 system to quantify the amount of CTCs in our patient cohort 
and to investigate the distribution of CTCs in the mesenteric venous blood 
compartment (MVBC) compared to the central venous blood compartment (CVBC).  
CRC - associated CTCs that are shed from the primary tumor reach the liver via the 
mesenteric and portal venous system before they enter the systemic circulation 
50
. Our 
study ought to provide data about primary hematogenous CTC dissemination and 
systemic hematogenous spread with regard to an assumed CTC filtering function of the 
liver. Furthermore, the presence of CTCs was correlated to various clinicopathological 
parameters. The study was conducted and supervised by our group member Dr. Rahbari 
and has been published 
104
. 
Blood samples of 200 CRC patients who underwent surgical resection for CRC in the 
department of surgery of the University Clinic Heidelberg between May 2009 and 
April 2011 were enrolled prospectively. Table 1 gives an overview about the study 
design and clinicopathologic characteristics of the study population. 
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Central venous blood of 200 patients was analyzed for the presence of CTCs whereas 
83 % of the analyzed blood samples showed no detectable CTCs. Univariate analysis 
(Table 2) confirmed that the number of patients with CTCs as well as the CTC amount 
correlated with the stage of disease. CTCs were detected in 10.2 % (19 of 142) of 
patients with UICC stage I-III and in 35.8 % (19 of 53) of UICC stage IV patients 
(p<0.0001). Stage I-III patients showed a mean amount of 0.2 (range: 0-5) CTCs per 
7.5 ml blood sample and 2.4 (range: 0-83) CTCs were detected in stage IV specimens 
(p<0.0001). Serum levels of CEA and CA 19-9 were associated significantly with 
detection of CTCs in central blood (Table 2).  
Regarding the detection of CTCs in MVBC data of 80 patients (40%) were available. A 
significant higher rate of patients with CTCs in the MVBC (35%, n=28) compared to 
the CVBC (17.5%, n=14) (p = 0.01) was found. Furthermore, the average number of 
CTCs was higher in the MVBC (mean 1.5, median 0, range: 0-32) than in the CVBC 
(mean 0.3, median 0, range 0-5) (p = 0.006) (Figure 9). CTCs in the CVBC were more 
frequently found (p = 0.01) and with higher number of tumor cells (p = 0.01) in patients 
with detectable CTCs in the MVBC. However, the presence of CTCs in the MVBC did 
not correlate with the staging of the disease (Table 3). Univariate association of 
clinicopathological variables with CTC presence and amount in MVBC showed that 
CTCs in the MVBC were detected at a higher rate (p = 0.02) and with higher quantity 
(p = 0.01) in patients with colon compared to patients with rectal cancer (Table 2). 
Correlations of tumor cell detection in MVBC to other assessed parameters were not 
found. 
In summary, we found that the number of patients with CTCs and the amount of CTCs 
was significantly correlated with the stage of disease. In addition, a significant higher 
rate of patients with CTCs in tumor-draining venous blood compared to the central 
venous blood was detected. 
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Tabel 1: Clinicopathological characteristics of the study population.  
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Clinicopathological parameter N (%) or median (range) 
Age 65 (27-86) 
Sex 
  Male 
  Female 
 
129 (64.5) 
71 (35.5) 
Site of disease 
  Colon 
  Rectum 
 
96 (48) 
104 (52) 
T stage 
  T0 
  T1 
  T2 
  T3 
  T4 
 
5 (2.5) 
13 (6.5) 
50 (25.0) 
107 (53.5) 
25 (12.5) 
N stage 
  N0 
  N1 
  N2 
 
114 (57.0) 
52 (26.0) 
34 (17.0) 
UICC stage 
  0 
  I 
  II 
  III 
  IV 
 
5 (2.5) 
45 (22.5) 
47 (23.5) 
50 (25) 
53 (26.5) 
Tumor differentiation 
  Moderate (G2) 
  Poor (G3) 
 
112 (77.2) 
33 (22.8) 
CEA 
  Elevated(> 2.5 U/l) 
 
65 (34.4) 
CA-19-9 
  Elevated (> 37 U/l) 
 
29 (15.3) 
 
 
Figure  9: CTC amount in central venous blood compartment (CVBC) and mesenteric venous 
blood compartment (MVBC) of CRC patients. 83% of patients were free of detectable CTCs in CVBC 
and 65% of patients were without CTCs in MVBC. 
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Table 2: Clinicopathologic correlations. Associations of clinicopathologic variables with tumor cell detection in the central and mesenteric venous blood compartment of 
patients with CRC (stage I – IV) 104 
 
 Central venous blood Mesenteric venous blood 
Characteristics Pt. with CTC  No. of CTC  Pt. with CTC  No. of CTC  
Age 
   ≤ 65 
   > 65 
 
20 (21.3) 
14 (13.3) 
0.13  
1.2 (0; 0 – 83) 
0.3 (0; 0 – 5) 
0.15  
16 (38.1) 
12 (31.6) 
0.54  
1.4 (0; 0 – 14) 
1.5 (0; 0 – 32) 
0.57 
Gender 
   Male 
   Female 
 
19 (14.7) 
15 (21.1) 
0.25  
0.3 (0; 0 – 5) 
1.6 (0; 0 – 83) 
0.23  
14 (28.0) 
14 (46.7) 
0.09  
1.0 (0; 0 – 14) 
2.1 (0; 0 – 32) 
0.04 
Site of disease 
  Colon 
   Rectum 
 
19 (19.8) 
15 (14.4) 
0.31  
1.4 (0; 0 – 83) 
0.2 (0; 0 – 4) 
0.23  
17 (48.6) 
11 (24.4) 
0.02  
2.4 (0.5; 0 – 32) 
0.7 (0; 0 – 14) 
0.01 
Stage of disease 
   I – III 
   IV 
 
15 (10.2) 
19 (35.8) 
<0.0001  
0.2 (0; 0 – 5) 
2.4 (0; 0 – 83) 
<0.0001  
16 (28.1) 
12 (52.2) 
0.04  
1.4 (0; 0 – 32) 
1.6 (1; 0 – 14) 
0.09 
T stage 
   T0-2 
   T3-4 
 
7 (10.3) 
27 (20.4) 
0.07  
0.1 (0; 0 – 1) 
1.1 (0; 0 – 83) 
0.04  
18 (33.3) 
10 (38.4) 
0.65  
1.0 (0; 0 – 14) 
2.4 (0; 0 – 32) 
0.48 
N stage 
   N0 
   N1/2 
 
14 (13.2) 
20 (21.3) 
0.12  
0.2 (0; 0 – 2) 
1.4 (0; 0 – 83) 
0.07  
13 (31.7) 
15 (38.5) 
0.52  
1.3 (0; 0 – 32) 
1.6 (0; 0 – 14) 
0.45 
 30 
Tumor differentiation 
   Moderate (G2) 
   Poor (G3) 
 
16 (14.3) 
7 (21.2) 
0.33  
0.3 (0; 0 – 5) 
0.7 (0; 0 – 5) 
0.26  
14 (30.4) 
6 (54.5) 
0.13  
0.8 (0; 0 – 14) 
5.0 (1; 0 – 32) 
0.06 
Resection margin 
   R0 
   R1/2 
 
28 (14.9) 
6 (46.1) 
0.004  
0.7 (0; 0 – 83) 
1.0 (1; 0 – 5) 
0.003  
24 (32.4) 
4 (66.7) 
0.09  
1.4 (0; 0 – 32) 
1.8 (1; 0 – 8) 
0.19 
Neoadjuvant therapy 
   Yes 
   No 
 
10 (16.7) 
18 (15.2) 
0.81  
0.2 (0; 0 – 4) 
0.34 (0; 0 – 5) 
0.89  
7 (25.9) 
12 (31.6) 
0.62  
0.5 (0; 0 – 5) 
1.8 (0; 0 – 32) 
0.45 
CEA 
   Normal 
   Elevated 
 
11 (8.9) 
20 (30.7) 
0.0001  
0.1 (0; 0 – 4) 
2.0 (0; 0 – 83) 
<0.0001  
16 (31.4) 
12 (48.0) 
0.16  
1.6 (0; 0 – 32) 
1.3 (0.5; 0 – 14) 
0.23 
CA 19-9 
   Normal 
   Elevated 
 
18 (11.3) 
13 (44.8) 
<0.0001  
0.2 (0; 0 – 5) 
3.9 (0; 0 – 83) 
<0.0001  
22 (33.3) 
6 (60.0) 
0.10  
1.5 (0; 0 – 32) 
1.2 (1; 0 – 4) 
0.15 
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Table 3: Detection of CTCs in mesenteric and central venous blood compartments and correlation to clinical staging.   
104
 
 
 Pt. with CTC P No. of CTC P 
Central venous blood vs. mesenteric venous blood (n = 80) 
    
   Central venous blood 
   Mesenteric venous blood 
 
 
14 (17.5) 
28 (35.0) 
0.01  
 
0.3 (0; 0 – 5) 
1.5 (0; 0 – 32) 
0.006 
Detection of CTC in mesenteric venous blood (n = 80) 
    
   Patients with CTC in central venous blood 
   Patients without CTC in central venous blood 
 
 
9 (64.3) 
19 (29.2) 
0.01  
 
2.0 (1; 0 – 14) 
1.3 (0; 0 – 32) 
0.02 
Detection of CTC in central venous blood (n = 80) 
   
   Patients with CTC in mesenteric venous blood 
   Patients without CTC in mesenteric venous blood 
 
 
9 (32.1) 
5 (9.8) 
0.01  
 
0.5 (0; 0 – 5) 
0.1 (0; 0 – 2) 
0.01 
Stage of disease (UICC) 
    
Central venous blood (n = 200) 
      0 
      I 
      II 
      III 
      IV 
 
Mesenteric venous blood (n = 80) 
      0 
      I 
      II 
      III 
      IV 
 
 
 
1 (20.0) 
3 (6.8) 
6 (12.7) 
5 (10.0) 
19 (35.8)  
 
 
1 (33.3) 
6 (37.5) 
5 (23.8) 
4 (23.5) 
12 (52.1) 
 
 
0.0007 
 
 
 
 
 
0.27 
 
 
 
0.2 (0; 0 – 1) 
0.1 (0; 0 – 1) 
0.2 (0; 0 – 2) 
0.3 (0; 0 – 5) 
2.4 (0; 0 – 83)  
 
 
0.3 (0; 0 – 1) 
2.7 (0; - 32) 
0.7 (0; 0 – 4) 
1.3 (0; 0 – 14) 
1.6 (1; 0 – 14) 
 
 
0.23 
 
 
 
 
 
0.68 
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Establishment of a reliable CTC enrichment and detection method 
 
We aimed to establish a protocol for an efficient enrichment and detection of CTCs that 
should provide the opportunity to analyze gene expression of the captured CTCs. The 
previously described study on CTC enumeration with the CellSearch
TM
 system showed 
that CTCs are hardly to find in blood samples of CRC patients. Therefore, high 
efficiency and sensitivity of the enrichment method is inevitably necessary. 
 
Magnetic beads fail to directly isolate EpCAM - expressing tumor cells  
A first attempt was designed to directly target EpCAM-expressing CTCs in the blood 
with the help of magnetic beads. Hence, DynaBeads coated with a set of different 
antibodies directed against EpCAM (Moc31, VU1D9, HEA125, BerEP4, KS1/4) and 
CEA (B1.1/CD66) were used. All antibodies were titrated to obtain the optimal 
concentration and ratio. Through the use of different antibody clones that were 
expected to target different epitops we supposed to increase the efficiency of the CTC 
enrichment. Spiking experiments with HT29 CRC cell line showed that direct 
enrichment with anti-EpCAM-coated magnetic beads is more efficient after density 
gradient centrifugation (Ficoll) compared to a direct use of magnetic beads in whole 
blood specimen. Efficiency was determined by RT-PCR for EpCAM and CK20 
expression (data not shown). However, the direct enrichment of spiked HT29 from the 
peripheral blood mononuclear cells (PBMC) was not superior to direct RNA extraction 
of the spiked PBMC pellet. Moreover, the high detection limit of 1000 spiked cancer 
cells and the strong carry-over of leukocytes made the method too inefficient for further 
considerations (data not shown). 
 
Leukocyte depletion with magnetic beads results in 10fold enrichment 
CD45 is a pan-leukocyte marker, which is normally absent on epithelial cells. It was 
decided to use CD45 to deplete leukocytes in blood samples and to enrich the residual 
CTC fraction. Figure 10 shows that the differential CD45 and EpCAM expression of 
leukocytes and tumor cells enables efficient leukocyte depletion and concomitant tumor 
cell enrichment. Even when low numbers of tumor cells were spiked an enrichment of 
more than 10 fold was possible (Figure 10). However, leukocyte carryover is still 
Results 
33 
C 
strong; therefore, further techniques are required to obtain pure CTC samples for 
mRNA expression analysis. 
 
 
Figure 10: Surface antigen expression allows identification of CTCs A: PBMC were spiked with 
SW480 colorectal tumor cells and stained for EpCAM and CD45. Tumor cells and leukocytes are 
detectable in clearly separated populations. B: Leukocytes that highly express CD45 are preferentially 
depleted by anti-CD45 coated magnetic beads leading to tumor cell enrichment. C: Different CRC cell 
lines (HT29, SW480, HD482, and HD835) were spiked in PBMC and subsequently enriched to 
demonstrate the efficiency of the described method. D: Low amounts of tumor cells were spiked in 
PBMC. The tumor cell enrichment by CD45 based leukocyte depletion was tested. DA: undepleted 
control, DB: unspiked, depleted control  DC: 0.5 % spiked, depleted, DD: 0.05% spiked, depleted, DE: 
0.01% spiked, DF: 0.005% spiked, DG: 0,001% spiked 
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Fluorescence-activated cell sorting (FACS) fails to isolate CTCs 
FACS sorting was considered to isolate CTCs out of leukocyte - depleted and EpCAM 
/ CD45 stained blood samples. Therefore, leukocyte specimens were spiked with 0.5% 
tumor cells. After leukocyte depletion with the help of magnetic beads and fluorescence 
staining a defined number of EpCAM
+
 /CD45
-
 tumor cells was sorted and mRNA-
expression analyzed. Despite a significant carryover of leukocytes, indicated by the 
detected CD45 mRNA in the samples (data not shown), it was decided to apply this 
method for patient material. Subsequently 17 patients’ blood samples, including ten 
patients that had overt liver metastasis and three sample of mesenterial blood were 
prepared and sorted with FACS Aria II
TM
. In each case between 20 and 100 cells were 
sorted as EpCAM
+
 /CD45
-
 by flow cytometry. Subsequent analysis by quantitative 
polymerase chain reaction (qPCR), however, revealed that these objects were probably 
unspecific fluorescent signals or no intact cells. Β-actin expression was detected in 
twelve samples, however, late in qPCR (Ct > 20) and it correlated in most cases to 
CD45 expression indicating a carryover of leukocytes. Only one sample showed a 
putative EpCAM expression close to the detection limit of the qPCR (Ct > 37).  
 
The micromanipulator enables the isolation of single CTCs  
Since cell sorting by flow cytometry was not successful and bears the risk of losing the 
rare CTCs, it was decided to apply a micromanipulator for CTC isolation. After density 
centrifugation and the aforementioned anti-CD45 beads based pre-enrichment strategy 
CTCs can be identified in stained blood samples with the help of fluorescence 
microscopy by using EpCAM-directed antibodies. Subsequently, the micromanipulator 
that is mounted on the fluorescence microscope allows the direct pipetting of single 
cells with the help of a small glass capillary (Figure 11). 
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Figure 11: The micromanipulator. Cells in suspension are picked with a micromanipulator (A) 
mounted on a microscope. Fluorescence microscopy allows the identification of stained cells. (B=Bright 
field, C=Nuclear stain /DAPI, D=Cytokeratin-PE staining) Subsequently, cells can be aspirated with the 
help of an exchangeable glass capillary (E +F). The picking of two aggregated CTCs is shown.  
 
A similar approach to isolate DTCs from bone marrow samples 
To assess if the developed CTC isolation protocol can be applied for the isolation of 
DTCs from bone marrow specimens as well we analyzed the expression of EpCAM 
and CD45 in a bone marrow sample of a healthy donator (Figure 12 A). The majority 
of bone marrow cells was found to express the leukocyte marker CD45. Therefore, 
depletion of bone marrow cells with the help of anti-CD45-beads is suitable for DTC 
enrichment. Despite a small portion of the bone marrow cells seem to express EpCAM 
to a low extent (EpCAM
low
) the identification of cancer cells spiked in the bone 
marrow samples is still possible because EpCAM expression in tumor cells 
(EpCAM
high
) was much stronger than in the BMDCs. Flow cytometry analysis 
displayed the cancer cell population clearly apart from the bone marrow cells indicating 
that the strong EpCAM expression of cancer cells allows the visual identification of 
DTCs by fluorescence microscopy (Figure 12 B).  
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Figure 12: Surface antigen expression enables identification of DTCs: A: Bone marrow samples 
were analyzed for the expression of CD45 and EpCAM. B: A bone marrow sample was spiked with 
HT29 cancer cells. Tumor cells can be distinguished from bone marrow cells due to the high expression 
of EpCAM. 
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An mRNA expression study on CRC - associated CTCs and DTCs 
 
We assume that tumor cell dissemination is associated with distinct changes in the 
mRNA expression profile. The present study ought to show if CTCs and DTCs display 
a specific transcriptional signature that differs from the corresponding cancer tissue. 
 
Validation of the cDNA amplification strategy for the analysis of single cells 
Despite remarkable progress during the last years, mRNA expression analysis of low 
cell numbers is still challenging and only possible if sophisticated amplification 
strategies are applied. To make sure that the intended amplification kit is suitable for 
the analysis of the low cell numbers ten and lesser cells were isolated for mRNA 
extraction. After cDNA amplification mRNA expression was assessed by quantitative 
RT-PCR. Figure 13 A shows that target gene mRNA expression of even single cells 
was detectable. For validation of the mRNA expression analysis ten tumor cells were 
isolated repeatedly in six independent experiments. The obtained mRNA was extracted 
and amplified. Subsequently, the relative expression of EpCAM, CK19 and CK18 
normalized to β-actin was examined (Figure 13). Since cells were cultured under equal 
conditions, we expected low inter-experimental variations of the analyzed genes. 
Despite single outliers the results showed comparable expression levels indicating the 
reliability of the used amplification technique. 
 
 
 
 
 
 
 
Figure 13: Validation of the cDNA amplification strategy. A RT-PCR analyses of low cell numbers. 
EpCAM expression of even a single HT 29 tumor cell was detectable. B Six independent target gene 
expression analyses of ten pooled tumor cells by RT-PCR normalized to β-actin. The tumor cells that 
were cultured under equal conditions show a comparable gene expression resulting in a low inter-
experimental standard deviation. 
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Unambiguous mRNA expression profiles of CTCs and DTCs reveal biological and 
therapeutic implications 
Between June 2010 and October 2011 72 blood samples and 9 bone marrow samples of 
CRC patients who underwent surgical resection for CRC in the department of surgery 
of the University Clinic Heidelberg were analyzed. Preferentially patients with overt 
liver metastases were selected to increase the chances to obtain blood samples 
containing CTCs. According to the results obtained from the CellSearch
TM
 system, that 
indicate a higher number of CTCs in the tumor draining veins, the blood was taken 
from a mesenteric vein or in case of liver metastases from the liver vein. CTCs were 
enriched and isolated as previously described by a manual enrichment protocol to 
enable the isolation of living cells. Figure 14 shows two images of CTCs as observed 
after EpCAM staining in a processed patient’s blood sample. Additional blood samples 
were analyzed by the CellSearch
TM
 system as an independent control of the used 
enrichment and isolation method.  
 
  
Figure 14: Human CTCs. CTC specimens from patient HD2095 stained with anti-EpCAM-Alexa488 
 
At least one CTC was detected in 56 % (40) of the samples by the CellSearch
TM
 system 
in blood samples obtained either from the mesenteric or the liver vein. However, in 
only 14 % (10) of the cases it was possible to successfully enrich CTCs from the blood 
and in 22% (2) of cases to isolate DTCs out of bone marrow samples. Mostly, CTCs 
were found with the manual enrichment approach only when high numbers of CTCs 
were detected by the CellSearch
TM
 system in parallel. CTCs/DTCs appeared usually as 
single cells. Surprisingly, cell clusters (tumor microemboli) were only rarely observed 
probably due to the applied enrichment procedure. Subsequently to the detection and 
Anti- EpCAM 
Alexa488 
Bright field 
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isolation CTCs/DTCs of single patients were pooled for RNA extraction and 
amplification (Table 4).  
 
Table 4: Patients characteristics. Overview about patients from whom CTCs or DTCs were obtained 
for mRNA expression analysis. No data about DTC incidence in bone marrow samples can be obtained 
from the CellSearch
TM
 system (indicated by X) since the device does not allow the processing of bone 
marrow samples. 
 
patient sex age UICC stage 
Blood 
sample 
(LV= liver 
vein, MV= 
mesenteric 
vein) 
No. of CTCs 
detected by 
CellSearch 
(7.5 ml 
blood) 
Manually 
isolated 
CTCs for 
mRNA 
expression 
analysis 
CTC 
HD 2091 male 57 IV LV 5 4 
HD 2095 female 69 IV LV 469 2 x 15 
HD 2130 female 57 IV LV 0 3 
HD 2201 male 64 IV LV 2 4 
HD 2231 male 62 IV LV 8 4 
HD 2257 female 55 IV LV 5 4 
HD 2288 female 59 IV LV 82 7 
HD 2334 male 73 III MV 208 3 x 8 
HD 2340 male 62 III MV 3 2 
 
DTC 
HD 2401 male 39 II bone 
marrow 
X 16 
HD 2417 male 70 IV bone 
marrow 
X 5 
 
Although mRNA expression analysis of single cells would be feasible, we decided to 
pool CTC populations to obtain more valid data and to increase the chances to detect 
even lowly expressed genes. Robust signals in qPCR were obtained when at least four 
cells were pooled for analysis. In addition, a similar number of cells from matched 
tissue of either primary tumor or liver metastases was taken to compare mRNA 
expression. Results are depicted in heat maps (Figures 15 – 18). A large-scale 
expression screen comprising 47 genes related to CTC/DTC identification, common 
CRC biomarkers, EMT, stemness and invasiveness were selected to describe 
CTC/DTC characteristics. In addition, we included CD45, a pan leukocyte marker that 
is not expressed on epithelial cells, in the study. Although it was a major aim to analyze 
CTC/DTC specimen without any disturbing background of leukocyte contaminations, it 
seemed to be impossible to obtain samples that were free of any CD45 signal in the 
qPCR. The ubiquitary presence of free leukocyte-derived CD45 mRNA in the patients’ 
samples probably leads to an unavoidable detection of CD45 mRNA in qPCR. Since 
we detected CD45 always in a comparable range among CTCs/DTCs and cancer tissue 
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samples, the similar CD45 signal in qPCR should be rather considered as technique-
derived noise. However, leukocyte carryover can not be excluded in general. Therefore, 
the supposed impurity of the specimens requires a cautious evaluation of the obtained 
expression profiles. In particular the expression of genes that are significantly 
expressed in the control leukocyte and bone marrow samples including CD44, 
Vimentin, CXCR4 and CD47 are difficult to assess. The robust signal of those genes in 
qPCR analysis indicates that they are expressed on tumor cells, however, it is difficult 
to state about their up or down-regulation during the dissemination process.  
 
CTC expression profiles reflect a fairly heterogeneous picture 
To compare general mRNA expression levels of CTCs and matched cancer tissue 
samples the Ct values obtained from qPCR data are depicted as heat map in figure 15. 
Since carryover of leukocytes might have introduced bias in the results; the mRNA 
expression profiles of three control leukocyte samples are shown in addition. The 
mRNA expression profile of CTCs is unambiguously distinct form leukocytes. The 
expression of EpCAM, CK18, CK19 and CEA in the CTCs and the absence of these 
markers in control leukocyte samples clearly confirmed the epithelial origin of the CTC 
specimens. EpCAM, CK18 and CK19 appeared to be well suited for CTC 
identification. CK20, however, seemed rather unstably expressed in CTCs. In addition, 
Ki67 was found to be absent or only lowly expressed in CTCs, which might indicate a 
proliferative arrest in CTCs. In general, gene expression of CTCs was found to be very 
heterogeneous. Unsupervised hierarchical clustering analyses using the Spearman rank 
correlation did not show a correlation among CTCs or among tumor and metastases and 
no matched correlation between CTCs and the corresponding cancer tissues (data not 
shown).  
With the present approach we were only able to evaluate the expression of a small 
panel of genes. Within this panel common traits of CTC samples seem to be limited to 
a few epithelial markers. Other genes seem to be expressed only occasionally in 
individual CTC specimens. For instance, the expression of stem cell markers like Bmi-
1 and Ascl2 was limited to CTCs of HD2201 or HD2095 respectively. The same 
applies for the pro-apoptotic protein Bax that was detected in CTCs of patients HD2095 
and HD2334 but not in other CTC specimens. Therefore, apoptosis seems to be 
attributed only to some CTCs, however, not a general feature.  
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Interestingly, it was not possible to confirm an enhanced expression of EMT-associated 
genes in CTCs. Although Vimentin seems to be expressed in CTCs, EMT-related 
transcription factors Snail and Twist as well as hFN, N-cadherin were mostly not 
detectable.  
 
 
Figure 15: mRNA expression of CTCs.  mRNA expression analysis of isolated CTC samples and 
matched samples of tumor (Tu.) or metastasis (Met.). Additionally, three leukocyte samples were 
analyzed to evaluate the influence of possible background carryover. Color scale represents ΔCt values 
of target and house keeping genes (β-actin). Low ΔCt values (yellow and green) indicate highly 
expressed genes. High ΔCt values (blue and purple) indicate lowly expressed genes. A white area 
indicates cases without available data.   
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CTCs rather resemble metastases than primary tumors in gene expression 
To compare gene expression between CTCs and the matched tissue samples two further 
heat maps are shown in figure 16. The representation of ΔΔCt values as color code 
facilitates the identification of differentially regulated genes among CTCs and matched 
cancer tissue samples. Interestingly, evaluated genes seem to be rather up-regulated in 
CTCs when compared to matched tumor samples, however, rather down-regulated or 
equally expressed when compared to liver metastases. For instance CD47, which was 
reported to be involved in immune escape 
105
, was found up-regulated in CTCs only 
when compared to tumor samples, however, equally expressed referring to metastases. 
Or the expression of the hyaluronic acid receptor and stem cell marker CD44s which 
seemed to be up-regulated in CTCs compared to primary tumor samples, but rather 
similar expressed referring to matched metastases. Other evaluated stem cell markers 
(CD166, Bmi-1, Lgr5, ZEB-1, and DLG7) were only rarely detected in CTCs and in 
the corresponding samples of tumor or metastasis. For CD133 no significant 
differential regulation was observed.  
With regard to EMT CTCs retained Vimentin expression after dissemination. If 
compared to tumor samples it seems to be even up-regulated. However, as previously 
mentioned Vimentin is expressed in leukocytes as well and since leukocyte carryover 
can not be excluded an up-regulation of Vimentin in CTCs can only be assumed. With 
further regard to EMT we were not able to show an up-regulation of mesenchymal 
genes like N-cadherin, Snail or Twist in the CTCs. Fibronectin expression seemed even 
to be lower expressed in CTCs than in matched metastasis samples. E-cadherin was 
found to be slightly down-regulated in CTC samples compared to the primary tumors; 
however, in comparison to metastases its expression was rather similar. The 
proliferation marker Ki67 seemed to be rather equally expressed among CTCs and 
cancer tissues. Genes attributed to apoptosis and survival, including p21, p53, Survivin 
and BAX, were not found to be differentially regulated. A significant up-regulation of 
metastasis-associated genes like CD44v6, CD26 or CO029 in CTCs was not observed.  
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Figure 16: Compared mRNA expression of CTCs and matched tumor (A) or liver metastasis (B). 
ΔΔCt values of ΔCt tumor/metastasis – ΔCt CTCs are depicted as heat map. Color scale indicates 
highly expressed genes of cancer tissue in yellow and green. Similar expression in both compartments is 
shown in faint green. Genes that are highly expressed in CTCs are depicted in blue and purple. A white 
area indicates cases without available data.   
A 
B 
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DTCs are probably dormant and lack EGFR expression 
Unfortunately, only mRNA expression data of two samples of DTCs is available 
(Figures 17 and 18). Despite this small number of specimens, a first trend seems to be 
evident. Unlike the CTCs the DTCs have lost CK19 expression in the bone marrow. 
Only CK18 and EpCAM expression was reliably detected in DTCs and confirmed the 
epithelial origin. E-cadherin appeared to be down-regulated. However, an up-regulation 
of EMT-associated genes was not detected. Analyses indicated that DTCs were 
probably non-proliferative and dormant as gene expression seemed to be in general 
down-regulated irrespectively if compared to tumor of metastasis (Figure 18). 
Numerous genes detected in tumor or metastases samples were not expressed in DTCs 
including the proliferation marker Ki67 as well as CD151, CEA, CD26, CO029 and 
EGFR. A significant expression of several CRC-associated stem cell markers, such as 
Lgr5, Ascl2 or ZEB1 was also not detectable. Olfm4 and DLG7 seem to be expressed 
in DTCs. However, these genes are expressed in control bone marrow samples as well. 
Since undesired carryover can not be excluded, expression of Olfm4 and DLG7 
requires independent confirmation.  
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Figure 17: mRNA expression of DTCs. mRNA expression analysis of isolated DTC and matched 
samples of tumor (Tu.) or metastasis (Met.). Additionally, three bone marrow samples were analyzed to 
evaluate the influence of possible background carryover. Color scale represents ΔCt values of target and 
house keeping genes (β-actin). Low ΔCt values (green) indicate highly expressed genes. High ΔCt values 
(blue and puple) indicate lowly expressed genes.  
 
 
Figure 18: Compared mRNA expression of DTCs and matched cancer tissue. ΔΔCt values of ΔCt 
tumor/metastasis – ΔCt DTCs are depicted as heat map. Color scale indicates highly expressed genes of 
cancer tissue in yellow and green. Similar expression is shown in faint green. Genes that are highly 
expressed in DTCs are depicted in blue and purple.   
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Genomic characterization of CTCs 
 
Today’s therapeutic approaches against cancer come away from just targeting rapid 
growing cells and try to interfere with specific pathways that are genetically altered in 
tumor cells. However, genetic and epigenetic heterogeneity is common in human 
cancers 
106, 107
. Thus, the need to determine the molecular profile of cancer cells to 
predict therapy response is becoming increasingly important.  With this study we want 
to assess the possibilities to characterize single CRC-associated CTCs on the genomic 
level in the strict sense of their mutational profile.  
 
CTCs carry typical point mutations in CRC-associated genes   
CRC-associated CTCs that were enriched and detected by the CellSearch
TM
 system 
were isolated as single cells with a micromanipulator to analyze their mutational 
profile. According to the CellSearch
TM
 guidelines CTCs were defined as EpCAM
+
 / 
CK
+
 (CK8, CK18, CK19 or in combination)/ DAPI
+
 / CD45
-
. A specific method to 
amplify gDNA of single cells published by Klein and colleagues 
108
 was applied to 
yield sufficient analyzable material. We were interested in common CRC-associated 
mutations including BRAF V600E, mutations in codons 12 and 13 in the KRAS gene, 
and aberrations within the DNA binding domain of TP53 (Figure 19).  
 
Figure 19: Mutation analysis.  Single CTCs were analyzed for mutations in BRAF (V600E), Kras 
(codon 12 and 13), and in the DNA binding domain of TP53 (exons 4-8) by direct sequencing. The 
figure depicts the included genomic regions. 
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It was possible to isolate and analyze between 1 and 14 CTCs from 31 individual 
patients (in total 126 CTCs) (supplementary figure 1). 68.8% of included patients were 
diagnosed as UICC stage IV, 21.9% UICC III, 3.1% UICC II, 6.2% UICC I 
(supplementary figure 2). In CTCs of 16 patients no mutations were detected within the 
evaluated genomic regions of interest. A mutation of codon 12 or 13 of the Kras gene 
was detected in CTCs of six patients (19.4%). The V600E mutation of BRAF was 
found in a CTC of one patient (3.2%). CTCs of eleven patients were found to carry a 
mutation in the DNA binding domain of TP53 (35.5%) (Table 5).  
 
Table 5: Overview about detected point mutations in CTCs. 
 Patients without a 
detected mutation 
Kras C12/C13 Braf V600E DNA-BD TP53 
No. of patients with 
indicated mutations 
(31 patients, 126 
CTCs, 1-14 CTCs per 
patient) 
16 (51.6%) 6 (19.4%) 1 (3.2%) 11 (35.5%) 
 
Identification of CTCs with MSI within coding and non-coding genomic regions 
MSI is a common phenomenon in CRC 
12
. Currently, conflicting data exist about the 
relevance of MSI for prognosis and therapy response in CRC 
109, 110
. We wanted to 
assess if the detection of MSI in amplified gDNA specimens of CTCs is possible. Since 
our single cell gDNA amplification approach depends on the sequence specific 
nuclease digestion by MSE I, it was not possible to include the same panel of MS 
markers that is recommended by the national cancer institute (NCI) (Bethesda 
guidelines) 
111
. Therefore, we typed CTCs at the three mononucleotide MS markers 
NR21, NR24 and BAT 25 that are widely accepted to indicate overall MSI in a cell 
112
.  
At least to our knowledge studies on MSI in amplified genomic specimens of single 
CRC-associated CTCs have not been reported until today. To exclude false positive 
typing, what might be caused by artifacts occurring during gDNA amplification, we 
included 35 normal leukocytes processed similarly to the CTC samples in the study. 
None of the analyzed leukocytes showed any signs of MSI within the evaluated MS.  
CTCs showing MSI were found in the blood samples of two patients (HD2215 and 
HD2341; 6.5%) (Figure 20). Those samples were subsequently analyzed for MSI in 
MS within coding genomic regions, so called coding microsatellites (cMS). The panel 
of cMS included Bax, DD5, FLT3LG and ELAVL3, because the mutation frequency of 
these MS-containing genes is well-known 
113
 and the applied gDNA amplification 
method did not interfere with their evaluation. The three analyzed CTCs of HD2341 
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showed MSI in at least two MS including NR21 and the cMS within ELAVL3 (Table 6). 
ELAVL3 codes for a RNA binding protein of the HuR family and is involved in the 
posttranscriptional regulation of mRNA expression. According to the recommendations 
of the NCI tumors with mutations in two of a panel of five MS are considered to have 
high MSI (MSI-H). If only one of the five MS is altered, the tumor is considered to 
have low MSI (MSI-L). Although it was not possible to evaluate the same set of MSI 
markers as suggested by the NCI, we typed the tumor cells of patient HD2341 as 
MSI-H because of two altered MS. In case of patient HD2215 two of nine typed CTCs 
showed MSI in NR21; however, no further MSI in any of the other analyzed markers 
was detected. Therefore, the aberration in only one MS marker refers to a MSI-L 
tumor. MSI-L was reported for various tumors including colorectal, breast, endometrial 
and ovarian cancers 
114, 115
 and might not be attributed to defects in cellular DNA 
mismatch repair systems. Instead, some DNA replication errors that occur 
stochastically and to a normal rate might have remained unrepaired due to an overload 
of the mismatch repair system as caused by high rate cell divisions in cancer.  
 
 
Figure 20: MSI in CTCs. Defects in DNA repair mechanisms can lead to lengthening or shortening of 
microsatellites (MS). Amplified length polymorphism (AFLP) analyses of CTCs and normal control 
leukocytes of patients HD2215 and HD2341 for NR21 (blue) and NR24 (green) are shown. Stutter bands 
arise since polymerase chain reaction amplification creates DNA fragments that are one or several 
repeats longer or shorter than the actual allele. Therefore, the highest detected peak was determined as 
the reference peak. Red peaks represent internal length control markers. Asterisks indicate the unchanged 
MS-length as detected in control leukocytes. Arrows indicate an altered MS length in single CTCs. For 
HD2215 CTC3 and HD2341 CTC1 no signal for NR24 was detected. This might be caused by losses of 
gDNA fragments during the single cell amplification procedure. 
HD 2341 
HD 2215 
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Table 6: cMS analysis of MSI
+
-CTCs. Three CTCs and one leukocyte (PBMC) of patient HD 2341 
were analyzed for microsatellite instability (MSI) within coding DNA regions.  No data was available for 
microsatellite sequence within BAX of CTC 2341 mes1 and 2341 PBMC1. MSI = microsatellite 
instability, MSS = microsatellite stable 
 
CTC NR21 NR24 BAX DD5 FLT3LG ELAVL 
2341mes1 MSI - - MSS MSS MSI 
2341mes2 MSI MSI MSS MSS MSS MSI 
2341mes3 MSI MSS MSS MSS MSS MSI 
2341 
PBMC1 
MSS MSS - MSS MSS MSS 
 
Inter - CTC genomic heterogeneity confirms clonal diversity 
In case of 16 patients more than one CTC could be analyzed. Six of those patients had a 
population of CTCs that were genomic heterogeneous (37.5%) with regard to mutations 
in Kras, BRAF, TP53 or MSI (supplementary figure 2). For instance, we have analyzed 
nine CTCs from the patient HD2215 for MSI (Table 7). Two CTCs were obtained from 
a blood sample of the liver vein (LV-CTC) and seven were isolated from mesenteric 
venous blood compartment (MV-CTC). Seven CTCs did not show any signs of MSI in 
the evaluated markers but two MV-CTCs showed MSI indicated by a changed allele 
length of NR21. Additionally, a Kras mutation was detected in four MS stable (MSS) 
CTCs of that patient whereas the mutation was not found in the MSI-CTCs. Another 
case of inter–CTC cytogenomic heterogeneity was found for patient HD2328 (Table 8). 
CTCs were isolated from blood samples obtained from the mesenteric vein and the 
liver vein. Astonishingly, one half of the analyzed CTCs (3/6) isolated from blood of 
the liver vein carried a mutation in exon 5 of the TP53 gene whereas the residual half 
did not. Intriguingly, we could not detect this mutation in CTCs obtained from the 
mesenteric blood compartment.  
In summary, it was possible to detect MSI and CRC-associated genomic mutations in 
single CTCs. In addition, we found cases of inter-CTC genomic heterogeneity in CTC 
fractions of single patients. The presence of various tumor subclones within a patient is 
reflected by different CTC populations that may have derived from different metastatic 
sites.  
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Table 7: Genomic inter-CTC heterogeneity of CTCs from patient HD 2215.   
CTCs and cancer tissue samples of patient HD 2215 were analyzed for microsatellite instability (MSI) 
and mutations within the indicated genomic regions. MSS = microsatellite stable, wt = wild type allele 
detected, n.d. = no data available. 
 
Patient 
sample 
/CTC 
Microsatellite 
stability 
Kras C12/13 Braf V600E TP53 E5/6 TP53 E7 TP53 E8 
2215 Tumor MSS G12S wt wt wt wt 
2215 liver 
met. 
MSS G12S wt wt wt wt 
CTC LV1 MSS G12S wt n.d. n.d. wt 
CTC LV2 MSS n.d. n.d. n.d. n.d. wt 
CTC mes 1 MSS n.d. n.d. n.d. wt n.d. 
CTC mes 2 MSS G12S wt n.d. wt wt 
CTC mes 3 MSI wt n.d. n.d. n.d. n.d. 
CTC mes 4 MSS G12S wt n.d. n.d. n.d. 
CTC mes 5 MSS wt wt wt wt wt 
CTC mes 7 MSI n.d. n.d. n.d. n.d. n.d. 
CTC mes 8 MSS n.d. wt n.d. n.d. n.d. 
 
Table 8: Genomic inter-CTC heterogeneity of CTCs from patient HD 2328.   
CTCs and a liver metastasis sample of patient HD 2328 were analyzed for microsatellite instability 
(MSI) and mutations within the indicated genomic regions. MSS = microsatellite stable, wt = wild type 
allele detected, n.d. = no data available. 
 
Patient 
sample 
/CTC 
Microsatellite 
stability 
Kras C12/13 Braf V600E TP53 E5/6 TP53 E7 TP53 E8 
2328 liver 
met. 
MSS wt wt F134C wt wt 
CTC LV1 MSS wt wt F134C wt wt 
CTC LV2 MSS wt wt F134C wt n.d. 
CTC LV3 MSS wt wt wt wt wt 
CTC LV4 MSS wt wt wt wt wt 
CTC LV5 MSS wt n.d. n.d. wt wt 
CTC LV6 MSS wt wt wt wt wt 
CTC LV7 MSS wt n.d. F134C n.d. wt 
CTC LV8 MSS wt wt wt wt wt 
CTC mes 1 MSS wt wt n.d. n.d. wt 
CTC mes 2 MSS wt wt wt wt wt 
CTC mes 3 MSS wt wt wt wt wt 
CTC mes 4 MSS n.d. n.d. n.d. n.d. n.d. 
CTC mes 6 MSS wt wt wt wt wt 
CTC mes 7 MSS wt wt wt wt wt 
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Malignant identity and chromosomal profile of single CRC-derived CTCs can be 
confirmed by matrix-CGH 
 
Chromosomal instability is a hallmark of CRC 
11
 and chromosomal aberrations were 
found to be of prognostic relevance 
116, 117
. However, if specific chromosomal 
alterations exist that are significant for the progression from invasive carcinoma to 
metastatic disease is still a matter of debate. We aimed to evaluate in a pilot experiment 
if the amplified gDNA of single CTCs is suited for a comparative genomic 
hybridization (CGH) analysis with regard to compare the genomic profiles among 
CTCs and solid cancer tissue. Therefore, array-CGH analyses of provided gDNA 
samples were performed in the lab of Prof. Dr. N. Stöcklein at the University Clinic 
Düsseldorf. To proof if pre-amplified gDNA from single cells allows the detection of 
genomic aberrations, amplified gDNA from two leukocytes were hybridized against 
each other on a 60k array (Figure 21). As expected, the ratio profiles are balanced for 
all autosomes. The genomic imbalance found for the sex chromosomes correctly 
reflects the different sexes of the two hybridized samples. 
 
 
Figure 21: Validation experiment. Amplified gDNA of single male and female leukocytes were 
hybridized against each other. The balanced ratio profile found for the autosomes confirms unbiased 
gDNA amplification. The genomic imbalance detected for the sex chromosomes (X, Y) correctly reflects 
the different sexes (male and female) of the samples.    
 
We analyzed in this pilot study the genomic profile of ten CTC samples with the help 
of a 180 k matrix-CGH array (supplementary figure 3). Three CTC samples were 
detected with a balanced CGH profile. Seven CTCs showed chromosomal aberrations 
that are typically found in CRC (Figure 24) (compare data base of University of Zurich: 
www.progenetix.org). These genomic aberrations comprised chromosomal gains in 
chromosomes 7, 8q, 13, 20 and losses in chromosomes 4, 8p, 18. Figure 24 depicts the 
penetrance plot of pooled data from all analyzed CTC specimens. The pilot study 
confirms that the evaluation of chromosomal instability in single CTCs is possible.  
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Comparing genomic profiles of CTCs to matched cancer tissue 
 
Today, individual therapy decisions rely on cancer tissue biopsies 
118
. To assess if the 
genomic profile of CTCs should be taken into consideration as well, we aimed to 
evaluate if the genomic profile of CTCs might differ from matched cancer tissue 
specimens.  
 
Patterns of mutations often differ among CTCs and matched cancer tissue 
The patterns of mutation of CTCs were compared with that of macro-dissections of the 
respective primary tumor or liver metastasis (Supplementary figure 1). For 26 of 31 
analyzed patients at least one of the included mutations was detected either in CTCs or 
in the corresponding malignant tissue. In 14 of 26 cases the detected mutations matched 
between the tissue and at least one analyzed CTC. A single time MSI analysis did not 
match between CTCs and malignant tissue. Sequencing results were not corresponding 
to each other eight times for Kras, three times for BRAF and three times for the 
sequenced region in TP53.  
 
CGH profiles of CTCs reflect individual clones of matched cancer tissue 
Additionally, array-CGH profiles of matched macro-dissected tumor or metastasis 
tissues could be generated for eight of the ten analyzed CTC samples (Supplementary 
figure 3). Seven tissue samples displayed typical CRC-associated genomic aberrations, 
one sample showed a balanced CGH profile without significant chromosomal changes. 
Twice the CGH profiles matched largely among the analyzed CTC and the matched 
cancer tissue. In six cases the CGH profiles appeared to be rather disparate between 
CTC and the matched cancer tissue sample.  
For instance, the CGH profiles a single liver vein - derived CTC and macro-dissected 
tissue from a liver metastasis of patient HD2095 showed a broadly similar 
chromosomal profile (Figure 22). Despite some disparate aberrations (chromosome 1q, 
2p and 17q), lots of identical chromosomal gains and losses indicate a common clonal 
origin of the analyzed specimens. Disparity might be attributed to the use of macro-
dissected tissue from the liver metastasis that represents the average of chromosomal 
aberrations found in the metastatic lesion.   
For liver a vein –derived CTC and liver metastasis of patient HD2288 we found largely 
disparate array-CGH profiles. We assume that the analyzed CTC does not reflect the 
prevailing clone of the metastasis (Figure 23). Figure 24 compares the accumulative 
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CGH penetrance plots of pooled CTC samples with pooled data obtained from array-
CGH analysis of tumor or metastasis tissue. Typical genomic aberrations associated 
with CRC were found. This includes chromosomal gains at chromosomes 7, 13, 20q 
and losses at chromosomes 4, 8p, 17p and 18q. 
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Figure 22: Array-CGH profiles of a liver vein - derived CTC and liver metastasis tissue of patient 
HD 2095.  The human set of chromosomes is shown (1-22, X, Y). Beside each chromosome the 
detected signal intensity of the array-CGH analysis is depicted. Amplitudes to the left reflect 
chromosomal losses. Amplitudes to the right reflect chromosomal gains. The detected chromosomal 
aberrations are broadly similar among CTC and metastasis tissue and might indicate a common clonal 
origin of the analyzed specimens.  
  
 
HD 2095 liver metastasis tissue 
HD 2095 CTC 
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Figure 23: Array-CGH profiles of a CTC and liver metastasis of patient HD 2288.  The human set 
of chromosomes is shown (1-22, X, Y). Beside each chromosome the detected signal intensity of the 
array-CGH analysis is depicted. Amplitudes to the left reflect chromosomal losses. Amplitudes to the 
right reflect chromosomal gains. The detected chromosomal aberrations are largely disparate among 
CTC and metastasis tissue and might indicate genetic clonal diversity of the analyzed cancer.  
HD 2288 liver metastasis tissue 
HD 2288 CTC 
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Figure 24: Accumulative penetrance plots of array-CGH data. A The penetrance Plots of pooled 
array-CGH results of CTC and cancer tissue samples are shown. Therefore, the human set of 
chromosomes (1-22, X, Y) was aligned and the frequency of detected aberrations was depicted. Arrows 
indicate typical CRC-associated chromosomal gains (red) and losses (green) found in both specimens. B 
For comparison of CGH profiles to database entries a penetrance plot provided by the university of 
Zurich (www.progenetix.org) is shown. The depicted plot includes CGH data of 1054 cases of CRC. 
Significant genomic aberrations shown in database were similarly detected in own analyses.  
 
 
CTCs 
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CTCs 
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An orthotopic mouse model of cancer cell dissemination 
 
As confirmed by own results, CTCs are rarely to find in blood samples of CRC 
patients. Therefore, we aimed to establish a model to mimic cancer cell dissemination. 
Animal experiments on cancer metastasis which inject tumor cells into the tail vein 
119
 
or the portal vein
120
 are little physiologic and omit initial steps of primary tumor growth 
and invasion. Ectopic animal models like subcutaneous tumor models 
121
 are easy to 
generate; however, most of them do not metastasize 
122, 123
. Thus, we decided to 
establish an orthotopic mouse model of metastatic CRC because the microenvironment 
in the host organ is known to have an enabling effect on metastasis 
124
. With the murine 
model it was intended to reproducibly obtain CTCs to a higher number than from 
human samples, because it is possible to take the total blood volume of a mouse 
through terminal heart puncture. Moreover, the disseminated cells would be of human 
origin; accordingly, possible contaminations with murine leukocytes would not 
influence the results of the target gene specific mRNA expression analyses.  
With the help of a microinjection system human CRC cells were injected into the cecal 
wall of the animals. First trials were started with Balb/c nu/nu mice. The nude mice 
lack a thymus which makes them incapable to generate mature T-cells and makes them 
suited for xenotransplantation 
125
. We decided to test different CRC cell lines including 
HCT116, LS174T, SW620, DLD1 and Colo205 for their potential of hematogenous 
dissemination in the nude mice. These cell lines were chosen because their use in 
orthotopic tumor models has already been described 
126, 127
. More than 80 % of the 
animals developed orthotopic tumors. Additionally, lymph node metastases were 
frequently observed (Figure 25). No DTCs were found in the bone marrow. Solely 
implantation of HCT116 lead to macroscopic liver (26%; n = 19) or lung (5% n = 19) 
metastases (Figure 26).  
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Figure 25: The orthotopic mouse model of CRC metastasis. The primary tumor (left), a lymph node 
metastasis (middle) and macroscopically visible liver metastases (right) of a xenotransplanted animal are 
displayed.  
 
 
Figure 26: Histological staining. A: H/E staining of tumor tissue. B-D: EpCAM staining of tumor (B), 
liver metastases (C) and micro-metastases in the lungs (D) of a HCT116 xenotransplanted animal. The 
red color indicates tumor cell - associated expression of human EpCAM. Nuclei appear blue due to 
counterstaining with hematoxylin.  
 
Of the tested cell lines, HCT116 seemed to be the only one with a tendency for 
hematogenous tumor cell dissemination. Therefore, further experiments were carried 
out only with HCT116. Immunohistochemistry and flow cytometry analysis of stained 
tissue samples from tumor, liver and lung metastases showed that the transplanted 
A 
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B 
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HCT116 cell line retains EpCAM expression after xenotransplantation which makes 
EpCAM a suitable marker for the detection of CTCs and DTCs in blood and bone 
marrow (Figures 26 and 27).  
 
Figure 27: EpCAM expression of HCT116 after xenotransplantation. Single cell suspension of 
primary tumor, liver and lung of a xenotransplanted mouse and a mock transplanted control animal were 
stained with anti-EpCAM-Alexa-488 antibody and analyzed by flow cytometry. EpCAM-expressing 
tumor cells (as indicated) were found in all analyzed tissues of the xenotransplanted mouse. 
 
29 animals that were xenotransplated with 2 x 10
6
 HCT116 cells developed a primary 
tumor but CTCs were only observed in five mice. As we were surprised of such a low 
frequency, we supposed that the level of immunodeficiency in Balb/c nu/nu mice 
sufficed to clear CTCs out of the blood. Consequently, it was decided to change the 
mouse strain to NOD/SCID/gamma mice. Currently, these mice are among to the most 
immunodeficient strains available 
128
. They lack mature T-cells, B-cells and natural 
killer cells and have defects in various cytokine signaling pathways. In addition, we 
decided to increase the potential for hematogenous dissemination by in vivo passaging 
of the cell line since this has been shown to augment the metastatic capability 
129
. Thus, 
instead of original HCT116 we used a sub-cell line that was obtained from an HCT116-
derived liver metastasis. This cell line is termed HCT116-P in the following. 
To assess tumor development and the point in time of tumor cell dissemination 
HCT116-P tumor cells were orthotopically transplanted into NOD/SCID/gamma mice. 
Tumor growth and appearance of CTCs were monitored over time (Figure 28). All 
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animals developed primary tumors, liver metastases and lung metastases. Liver and 
lung metastases were assessed by histological staining (H/E staining). Liver metastases 
appeared between day 14 and 21, lung metastases developed between day 21 and day 
28. Beyond that, the CTC amount in cardiac blood was determined as well. No CTCs 
were found before day 25 post tumor cell injection (ptci). 
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Figure 28: Tumor development. Graphs show the time-dependent increase of tumor size and weight. 
 
Within 30-35 days all animals developed tumors of a mean weight of 0.3 g (Figure 28). 
At this stage lymph node metastases and macroscopic visible liver metastases were 
seen in all mice. A correlation of tumor weight to CTC amount was not found. No 
DTCs were found in the bone marrow.  
It was possible to isolate CTCs from eight mice. The amount of CTCs varied between 
the animals from zero to several hundreds of CTCs. Isolated CTCs were viable and 
formed colonies when cultivated in vitro (Figure 29). Morphological characteristics and 
the expression of EpCAM confirmed tumor cell identity and human origin of the 
adhesive cells. Moreover, the CTC-derived cell line induced tumor growth in 
NOD/SCID/ gamma mice when injected subcutaneously. 
Cancer progression can lead to the accumulation of fluid in the peritoneal cavity which 
is called acites. Xenotransplanted mice suffering from advanced cancer developed 
ascites containing thousands of tumor cells. Tumor cells that have disseminated into the 
ascites are termed AS-CTCs in the following. 
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Figure 29: Colony formation of CTCs isolated from 
murine blood. CTCs isolated from mouse blood form 
colonies in vitro. 
 
CTCs and AS-CTCs were stained6 with an EpCAM antibody for identification and 
isolation. Figure 30 shows that the staining intensity due to different EpCAM 
expression varies strongly among AS-CTCs. CTCs found in blood and ascites appeared 
often as cell clusters (Figures 30 and 31).  
 
 
 
 
Figure 30: Fluorescence staining of AS-CTCs. AS-CTCs of a xenotransplanted animal were stained 
for membrane-bound EpCAM. A AS-CTCs and residual leukocytes in bright field. B Green fluorescence 
of anti-EpCAM-AlexaFluor 488 stained AS-CTCs. Different fluorescence intensity indicates variations 
in the protein expression levels among the AS-CTC.  
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Figure 31: Fluorescence staining of CTCs. CTCs that were detected in murine blood are depicted in 
bright field and under green fluorescence after EpCAM specific fluorescence staining. CTCs detected in 
blood have a different appearance. Often different patterns of cell clusters were observed. 
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mRNA expression profiling reveals different gene expression patterns  
In each case about 15 cells of primary tumor tissue, of CTCs and of AS-CTCs were 
isolated and processed for mRNA expression analyses. After mRNA isolation and 
cDNA amplification the gene expression was evaluated with regard to cancer-
associated biological traits like proliferation, cell cycle, stemness, metastasis and EMT. 
Reliable results of the conducted expression analyses were available for 17 tumors, 9 
CTC and 18 AS-CTC samples obtained from eight mice. As expected, gene expression 
analyses of low cell numbers varied strongly. This might be attributed mainly to 
fluctuations in mRNA expression within individual cells. Therefore, common changes 
in gene expression require statistical evaluation and can only be detected if numerous 
samples are analyzed. Figure 32 gives an overview of the relative expression values. 
With regard to target gene expression CTCs resemble AS-CTCs. Comparing in vitro to 
in vivo culture of HCT116-P cells revealed most changes in the transcriptional profile. 
Genes that might be differentially regulated during tumor cell dissemination include E-
cadherin, Snail, CD44s and EGFR as shown by comparing CTC with tumor mRNA 
expression. 
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Figure 32: Comparison of mRNA expression.  Transcript intensities are correlated between (A) CTCs 
and AS-CTCs, (B) unprocessed HCT116-P cells and tumor, and (C) CTCs and tumor. For reasons of 
clarity and comprehsibility standard deviation is only shown for selected genes. CTCs and AS-CTCs are 
transcriptionally similar. Unprocessed HCT116-P compared to HCT116-P-derived tumors display most 
differences in transcript intensity. High Ct values indicate a low gene expression. 
 
CTCs maintain epithelial traits 
To confirm the epithelial and human identity of the isolated CTCs expression of 
EpCAM, CK19 and CK18 was tested. Despite remarkable variations of transcript 
intensities the expression of the three assessed epithelial markers was constantly 
detectable. Figure 33 indicates that the expression of the epithelial markers is 
maintained during dissemination and no significant expression changes took place.  
This confirms that EpCAM, CK19 and CK18 are suitable and reliable marker genes for 
the detection of disseminated tumor cells. 
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Figure 33: Expression of epithelial markers in CTCs. EpCAM, CK19 and CK18 expression of tumor 
tissue, CTCs and AS-CTCs normalized to β-actin are shown. No significant changes in mRNA 
expression among those genes were detected. 
 
CTCs lack signs of EMT 
To support the hypothesis that disseminating tumor cells undergo a change to a rather 
mesenchymal phenotype, specimens were tested for the expression of EMT-inducing 
transcription factors including Twist, Snail and ZEB1. Expression of Twist and ZEB1 
was not detectable in any of the samples. Snail expression was found to be slightly up-
regulated in CTCs (2 fold) and AS-CTCs (3 fold) samples; however, statistical 
evaluation did not confirm significance. Since EMT can be induced through numerous 
pathways, the expression of EMT target genes was analyzed, too. Although an average 
down-regulation of E-cadherin in CTCs (106 fold) and AS-CTCs (32 fold) compared to 
tumor samples was observed, data failed to reach statistical significance. N-cadherin 
and hFN expression were not detectable in the samples. Vimentin expression was 
detected in the specimens but expression was not significantly different among tumor 
and disseminated cells.  
 
CTCs stop proliferation and up-regulate anti-apoptotic Survivin 
To assess if disseminated cells persist in a dormant, non-proliferative state and if they 
are prone to undergo apoptosis the expression of Ki67, Cyclin D1, c-myc, β-Catenin, 
p53, p21 and Survivin was examined. Despite strong variations of mRNA expression 
levels, an up-regulation of Survivin was found in CTCs (4.6 fold, p=0.004) which was 
statistical significant (Student’s t-test, p < 0.05) (Figure 34). The proliferation marker 
Ki67 was significantly down-regulated (10 fold, p = 0.04) in AS-CTCs, indicating a 
presumable proliferation arrest (Figure 34). No signs for differential gene expression 
were found for Cyclin D1, c-myc, β-Catenin, p53 or p21. 
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Figure 34: mRNA expression of Survivin and Ki67. Survivin and Ki67 expression was assessed in 
tumor, CTCs, AS-CTCs and in unprocessed HCT116-P cells. Survivin was found to be significant up-
regulated in CTC samples potentially protecting CTCs from apoptosis. The down-regulation of the 
proliferation marker Ki67 in AS-CTCs seems to indicate a proliferation arrest in AS-CTCs as a 
consequence of long-term dissociation from the primary tumor site. Statistical significance was 
determined by Student’s t-test. P - values below 0.05 were considered as statistical significant. 
 
No significant changes in the expression of stem cell markers in CTCs 
Samples have been analyzed for the expression of stem cell-associated markers. 
Expression of Olfm4, Ascl2 and Lgr5 has not been detected in the specimens. In case 
of CD133, CD166, Bmi1, EGR1 and DLG7 no significant differences in gene 
expression were found. 
 
Most metastasis-associated genes are equally expressed in CTCs and tumor samples 
The expression of EpCAM, CD44v6, CO029, CD151 and CLDN7 facilitates metastasis 
formation in CRC 
130
. Therefore, we aimed to evaluate the expression of these genes in 
our mouse model. However, no significant differences in the expression of EpCAM, 
CD44v6, CD151 and CLDN7 were found. The expression of the tetraspanin CO029 
was not detected. Interestingly, CD44s was found to be significantly up-regulated in 
CTCs (p= 0.017; 9.4 fold) and in AS-CTCs (p=0.03; 8.4 fold) as compared to tumor 
samples (Figure 35). Additional metastasis-associated genes including MMP7, CXCR4 
and CD26 seemed not to be differentially regulated. EGFR was found to be down-
regulated (5 fold) in CTCs compared to tumor samples but failed to reach statistical 
significance (Figure 35).  
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Figure 35: mRNA expression of CD44s and EGFR Relative expression of CD44s and EGFR was 
measured by RT-PCR. Statistical significance was determined by Student’s t-test. P - values below 0.05 
were considered to be statistical significant. Significant differences of CD44s mRNA expression were 
found between tumor and CTCs specimens. EGFR expression failed to reach statistical significance 
among the different subgroups.  
 
 
In summary, our mouse model of metastatic CRC provides the opportunity to study 
differential gene expression during the process of tumor cell dissemination. We found 
that the expression of epithelial markers including CK18, CK19 and EpCAM is not 
significantly altered after the dissemination. Although down-regulation of E-cadherin 
seems to support metastasis, convincing signs of EMT in the disseminated cells were 
not found. However, the detection of differentially expressed genes like Survivin and 
CD44s, that were found to be up-regulated in CTCs, might allow first conclusions 
about the mechanism of tumor cell dissemination.  
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Discussion 
This thesis provides comprehensive data about the detection, isolation and 
characterization of CRC - derived CTCs and DTCs. Beside an own study on CTC 
incidence in blood samples of CRC patients, we provide intriguing data about genomic 
and transcriptional profiles of CTCs and DTCs. In addition, we established an 
orthotopic mouse model to mimic cancer cell dissemination. To my knowledge a 
comparable wide-ranging approach to elucidate the molecular mechanisms of tumor 
cell dissemination has never been reported before. 
 
Compartmental differences of CTCs in CRC 
 
To study the CTC amount in our patient cohort we used the FDA-cleared CellSearch
TM
 
system. We analyzed blood samples from the CVBC, which were either obtained from 
the internal jugular or subclavian vein, and blood samples from the MVBC, which 
were collected from a tumor-draining mesenterial vein. Blood was taken shortly before 
surgical tumor resection and allowed the evaluation of compartmental differences of 
CTC distribution in both venous compartments. We could confirm that the detection of 
CTCs in central venous blood correlates to the stage of disease 
53
. CTCs were found 
rarely and in low numbers in blood samples of patients with early stages of CRC. 
Therefore, the use of CTC detection systems for prognostic and therapeutic purposes 
might be largely limited to advanced stages of CRC. The low number of CTCs that are 
detected in early cancer stages is usually below the dynamic range required for 
measuring treatment response.  
Following the pathways of tumor cell dissemination in CRC we have compared the 
distribution of CTCs in central and mesenteric venous blood. CTCs were found to be 
more frequently present and with higher numbers in MVBC than in CVBC. Previous 
studies 
131-134
 that have analyzed the presence of CTCs in the mesenteric venous blood 
of CRC patients are in line with our findings. However, those studies relied mainly on 
RT-PCR to detect the expression of CEA or cytokeratins and did not allow the exact 
enumeration of CTCs. Our data supports the cascade theory in CRC assuming a 
stepwise tumor progression with the liver acting as a filter for CTCs 
50
. The detection 
of CTCs in central venous blood indicates that the filtering function of the liver seems 
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to be incomplete. We found an increased quantity of CTCs in CVBC in patients with 
CTCs in the MVBC suggesting an amount-dependent filtering of CTCs in the liver. 
The development of overt metastases causes further dissemination of CTCs into the 
circulation which is supported by the findings that the CTC amount in CVBC increases 
considerably in patients with stage IV disease and that the presence of liver metastases 
was found to be a strong and independent factor associated with CTC detection in the 
CVBC but not in the MVBC. Although various studies 
53, 132
 regarding the association 
of clinicopathologic variables with the detection and count of CTCs in mesenteric and 
central venous blood already exist, there has been no concomitant evaluation of CTC 
incidence in CVBC and MVBC using the standardized CellSearch
TM
 system. An 
elevated preoperative CA 19-9 level was found to be independently correlated with the 
presence of CTCs in the CVBC. CA 19-9, which has been widely used as a tumor 
marker, is a sialylated Lewis blood group antigen and a ligand for the endothelial cell 
adhesion molecule E-selectin 
135
. Several studies have shown that the preoperative 
serum CA 19-9 levels are associated with a poor prognosis for patients with CRC 
136, 
137
. Beside the function of CA 19-9 in adhesion of CTCs to the endothelium, our data 
might suggest that CA 19-9 could possibly be involved in the detachment of tumor 
cells from the primary tumor and in CTC persistence in the systemic circulation. 
The prognostic relevance of the detection of CTCs in the mesenteric compartment is 
still controversial. A meta-analysis 
84
 of the few available studies was not able to 
confirm a significant association of mesenteric CTCs with disease recurrence and 
survival whereas CTC detection in the peripheral/central blood was a strong predictor 
of poor outcome. Our data revealed that CTC detection in the MVBC is only weakly 
correlated to the assessed clinicopathological variables and is in line with the 
inconsistent finding of previous studies. Therefore, we suppose that most of the CTCs 
that are found in the MVBC are not of clinical relevance. Probably, most of CTCs that 
are shed into the circulation can not adapt to the foreign microenvironment and die 
quickly 
41-43
. However, CTCs that are found in the CVBC have proved their ability to 
survive in the systemic circulation and have accomplished a further decisive step on the 
way to malignant progression.  
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Establishment of a reliable CTC enrichment and detection method 
 
mRNA expression studies on CTCs and DTCs are essential for understanding the 
biology of the initial steps of the metastatic cascade. Since standardized methods for 
CTC/DTC isolation are lacking, own approaches for single cell analyses had to be 
developed and evaluated. The right choice of suitable CTC markers appeared to be a 
major problem. Since intracellular proteins such as cytokeratins require the 
permeabilization of cells for staining, they were not eligible to obtain intact cells 
required for mRNA expression studies. We decided to focus on EpCAM as epithelial 
surface marker. EpCAM is widely used for the detection of CTCs in blood samples of 
cancer patients since it is absent on leukocytes. Also the CellSearch
TM
, the only FDA-
approved, standardized system for CTC enumeration in various cancers makes use of 
EpCAM as initial CTC marker 
85
. Nevertheless, EpCAM remains controversial because 
it is described as a cell surface protein with functions in cell-cell adhesion that might 
counteract tumor cell shedding. In 2009 Sieuwerts et al. 
138
 reported that some breast 
cancer cell lines even lack EpCAM expression. In addition, some authors 
40, 139
 claim 
that epithelial genes such as cytokeratins and EpCAM might be down-regulated in the 
course of EMT which is assumed to be critically linked to tumor cell dissemination. 
Although a general presence of EpCAM on CTCs might be uncertain, a total loss of 
EpCAM on CRC - associated CTCs has not been shown so far. Despite concerns 
EpCAM is presently at least to our opinion the best suited marker to distinguish 
epithelial cells from leukocytes in human blood samples. Therefore, we have decided to 
use EpCAM as an eligible marker for CTC detection.  
Comparing the efficiency of our manual CTC enrichment approach to the standardized 
CellSearch
TM
 system revealed that CTCs were detected to a lower number and less 
frequently applying the manual protocol. Whereas the CellSearch
TM
 applies ferrofluidic 
nanoparticles and strong electromagnets to enrich CTCs, our method depends on 
leukocyte depletion by relative large magnetic beads that are removed with simple 
ferromagnets. In addition, our approach requires searching for CTCs under a 
fluorescence microscope by the unaided eye. This might not be as efficient as it can be 
achieved with the sensitive camera system that is used in the CellSearch
TM
. 
Nevertheless, our manual CTC enrichment method enabled the detection of intact 
CTCs and with the help of the micromanipulator it has been possible to directly isolate 
single CTCs without a strong leukocyte carryover. Establishing a functional CTC 
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detection and isolation protocol has been decisive for the following study on mRNA 
expression in CTC samples. 
 
A mRNA expression study on CRC - associated CTCs and DTCs 
 
At least to our knowledge, here, we describe for the first time a study on the mRNA 
expression of almost 50 genes in nearly pure fractions of CRC-associated CTCs and 
DTCs. CTCs/DTCs are rare and only to find in a strong background of leukocytes or 
bone marrow cells, which is a major obstacle for their molecular analysis. The impurity 
of the CTC/DTC fractions used in previous reports on their transcriptional signatures 
has been a substantial drawback of these studies 
100-102
. Analyzing rare CTCs in a 
strong background of several thousands of leukocytes is mainly limited to the detection 
of genes that are exclusively expressed by CTCs and can therefore only be used to 
define novel CTC markers. However, an unbiased evaluation of mRNA expression in 
CTCs/DTCs requires pure cell samples. With our micromanipulator-based method that 
allows the pipetting of single cells, we aimed to obtain CTC/DTC samples free of any 
leukocyte carryover. Despite promising results with blood samples spiked with cancer 
cells, it was, however, not possible to isolate CTCs/DTCs from patients’ blood samples 
lacking any CD45 mRNA signal. CD45 was actually intended to measure leukocyte 
carryover; however, some researchers recently reported co-expression of CD45 with 
epithelial markers in CTCs of some patients with different kinds of cancer 
140
. At the 
moment we can only speculate about a putative contribution of CTCs to the detected 
CD45 signal. Further efforts are needed to clarify if CD45 is attributed exclusively to 
leukocytes or if it is at least occasionally expressed on CTCs as well. In addition, it was 
recently reported that CTCs might avoid NK cell-mediated lysis through the 
aggregation with platelets 
47, 48
. Moreover, Pawelek et al. have suggested that CTCs 
might fuse with BMDC in the blood 
49
. Both scenarios could lead to the CD45 
detection in the specimens. Probably, our CTC/DTC samples are not absolutely free of 
any leukocyte carryover; nevertheless, the leukocyte background has been considerably 
reduced compared to other studies 
100-102
. The detected CTC/DTC expression profiles 
are distinct from profiles of leukocytes or cells of the bone marrow and show a unique 
expression signature. Epithelial markers such as EpCAM, CEA, Calreticulin, CK18 and 
CK19 indicate a substantial amount of cancer cells in the evaluated samples. Generally, 
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a strong heterogeneity among the CTC/DTC specimens was observed which might 
indicate the existence of various CTC/DTC subpopulations.  
Although mRNA expression analysis of single cells would be feasible, we decided to 
pool CTC populations to obtain more valid data and to increase the chances to detect 
even lowly expressed genes. Studies on gene expression in single cells or small cell 
pools are challenging until today. A large scattering of detected mRNA expression 
levels has to be expected since transcription is rather a stochastic than a continuous 
process 
141
. The inherent randomness in transcription impedes the precise phenotypic 
determination of individual cells. Particularly, the noisy transcription of lowly 
expressed genes requires large numbers of samples and statistical evaluation to state 
significant trends.  
 
CTC samples 
In this pilot study CTC samples from only ten patients were evaluated, common 
findings are therefore limited but some remarkable aspects are worth discussing. 
Interestingly, some genes, including CD47, CD44s and Vimentin seem to be up-
regulated in CTCs when compared to tumor tissue, however rather similar expressed 
when referred to metastasis samples. It might be conceivable that the expression of 
some metastasis-associated genes in CTCs resembles the metastases rather than the 
primary tumors. For instance high expression of CD47, which might be involved in 
tumor immune escape 
105
, might be necessary for CTC survival in the circulation but 
could be favorable for metastatic growth as well. Probably, metastases maintain at least 
to some extend the expression profiles they already gained during the early steps of 
tumor cell dissemination. E-cadherin is another example supporting this hypothesis. E-
cadherin was found to be down-regulated in the CTC samples when compared to 
primary tumors, however similarly low expressed as detected in metastases samples. 
Lower expression of E-cadherin in metastases compared to matched primary tumors 
was already reported for CRC 
142
; hence, the reduced expression of cell-cell adhesion 
molecules seems to be crucial for tumor cell detachment. However, our results do not 
confirm a significant contribution of EMT to tumor cell dissemination. It is widely 
reported that EMT might be a prerequisite for metastasis 
39
 but our CTC samples seem 
to lack expression of various putative inducers of a mesenchymal transition including 
Twist and Snail. Furthermore, an up-regulation of mesenchymal genes was also hardly 
detectable. One might argue that our CTC identification method relies exclusively on 
Discussion 
74 
the epithelial marker EpCAM and therefore could miss CTCs that have undergone 
EMT and lack expression of epithelial proteins. Recent studies 
139
 with the ISET 
system, a CTC detection method depending on size-dependent filtration, have shown 
the presence of non-small-cell lung cancer-associated CTCs that did not express 
epithelial markers. However, at least to my knowledge neither the existence of CRC-
associated CTCs lacking the expression of epithelial markers nor the contribution of 
such cells to cancer staging or prognosis has been reported so far. In addition, if 
mesenchymal-transformed tumor cells are able to initiate metastasis is highly 
controversial at all 
57
 
143
. On the other hand the impact of EpCAM
+
 - CTCs on cancer 
prognosis was confirmed several times 
86
 
87
.  
It was reported, that CTCs are frequently apoptotic 
144
. We did not detect the 
differential regulation of apoptosis related genes such as Bax, Survivin, p53 and p21 in 
our samples. However, our CTC samples were obtained from tumor or metastasis 
draining vessels and not from peripheral blood samples; therefore most of the analyzed 
CTCs have probably just detached from the solid cancer tissue and represent only a 
snapshot of an assumed heterogenic CTC population. Apoptosis might occur delayed 
and after a longer exposure to shear stress and the loss of cell-cell contacts. 
Interestingly, we did not find an up-regulation of metastasis-associated genes, including 
CD44v6, CO029 and CLDN7 in the CTC samples. Despite convincing reports 
130, 145
 
that these genes indicate aggressive tumor growth and metastatic spread, their 
expression seemed not to be attributed to the analyzed CTC samples.  
We found the proliferation marker Ki-67 absent or down-regulated on CTC samples 
which is in accordance to a study about breast cancer-associated CTCs 
146
. Although 
we can not exclude that proliferating CTCs exist, a proliferative arrest might be useful 
for CTCs to adapt to the foreign microenvironment in the blood. Interestingly, we did 
not detect the down-regulation of β-catenin which would additionally indicate a low 
proliferation of CTCs since it is a main part of the Wnt signaling pathway 
147
. However, 
regulation of the Wnt pathway might be achieved post-transcriptionally as well 
148
.  
 
DTC samples 
It was only possible to include two samples of DTCs isolated from the bone marrow of 
CRC patients in this pilot study. We were able to identify DTCs due to EpCAM 
expression amongst a strong excess of bone marrow cells. Detection of CK18 
confirmed the epithelial origin of the DTCs. Despite CK20 is the most commonly used 
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marker for DTC detection in RT-PCR analyses 
90
, no CK20 mRNA expression was 
detected in our DTC specimens. Together with the lost CK19 expression this might 
indicate signs of an occurred de-differentiation in the cells and questions the use of 
CK19 and CK20 as DTC markers. The gene expression profile of DTCs seems to be 
distinct from their corresponding primary tumors or metastasis. In particular with 
regard to systemic therapeutic approaches the molecular characterization of DTCs 
might have enormous therapeutic impact. For instance, DTCs, that we have analyzed, 
seem to lack EGFR expression which might mediate chemotherapy resistance and 
explain limitations of anti-EGFR based therapies in systemic treatment.  
The proliferation marker Ki67 was also not detected in DTCs. This is in line with other 
reports that describe DTCs mostly as non-proliferative and dormant cells 
146, 149
. 
However, DTCs might be able to escape proliferative dormancy when supplied with 
appropriate growth factors as shown by cell culture experiments 
150
. DTCs that are 
hidden throughout the whole body are highly suspicious to cause cancer relapse even 
years after primary tumor resection 
58
. Thus, to reduce cancer reoccurrence therapeutic 
regimens are required that effectively target DTCs. Since the molecular traits of the 
primary tumor are probably distinct from DTCs, the development of successful 
therapies calls for further ambitious studies on the characterization of DTCs. 
 
Genomic characterization of CTCs  
 
The present study combined the standardized CTC-enumeration of the CellSearch
TM
 
system with the concomitant genotyping of clearly defined and detected CTCs. Single 
CK-positive stained cells were isolated with a micromanipulator mounted on a 
fluorescence microscope for the subsequent global amplification of the gDNA. To 
evaluate the possibilities to characterize CTCs on the genomic level we searched for 
point mutations in Kras, BRAF and TP53 as well as for signs of MSI. In addition, some 
cells were used for global array-CGH analysis. Point mutations, MSI and chromosomal 
instability have been associated with survival, prognosis or therapy response in CRC. 
For instance, mutations of Kras and Braf indicate a lack of therapy response to anti-
EGFR monoclonal antibodies like cetuximab and panitumumab 
151-153
 which is caused 
by the constitutive activation of the Ras-MAPK pathway 
154
. Mutated TP53 has been 
associated with survival 
155, 156
 and therapy response 
157
. MSI and specific chromosomal 
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losses or gains were found to be of prognostic relevance 
158-162
 as well. Therefore, the 
genomic characterization of CTCs might provide an opportunity to improve prediction 
of prognosis and to adapt therapy regimes to the genetic aberrations of individual 
tumors. With the present study we were able to show that epithelial cells detected with 
the CellSearch
TM
 carry CRC-associated mutations and we provide evidence that these 
cells are of malignant origin. Despite a limited number of samples we detected 
remarkable inter-CTC heterogeneity in CTC fractions obtained from single patients. Of 
the 17 patients from whom we were able to analyze more than one CTC a genetic 
disparity among CTCs of a single patient was found in six cases (37.5%). Genomic 
heterogeneity of CTCs seems to be a common phenomenon and an evidence for 
genomic instability and clonal diversity in CRC. A study from Fehm and colleagues 
163
, 
that mainly included cases of breast cancer, reported heterogeneous CTC pools in 13 of 
20 cases (65%). However, they used in-situ hybridization for the detection of 
aneusomie. Since their approach covers more potentially mutational sites, the higher 
detection rate might thus be explained. The presence of genomic heterogenic CTC 
populations further complicates the selection of appropriate therapy regimens and 
might require the analysis of a number of representative CTCs when individual tailored 
therapy is intended. 
In addition, we aimed to evaluate to what extend the detected genomic aberrations 
correlate among CTCs and matched cancer tissue. In twelve of 26 cases we found 
disparate genotypes for CTCs compared to cancer tissue. Intriguingly, a high portion of 
disparate genotypes (CTCs vs. cancer tissue) was found for Kras and BRAF whereas 
disparity was less frequently observed for TP53. Typically, inactivating mutations of 
tumor suppressor genes like TP53 are found homozygous 
164
. Oncogenes like Kras or 
BRAF, however, often carry activating mutations in only a single allele and are 
therefore heterozygous 
165
. One might argue that the applied single cell gDNA 
amplification technique can not reliable detect heterozygous mutations. Due to the low 
amount of gDNA of a single cell some DNA fragments could fail to be amplified and 
thus cannot be detected in sequence specific PCR. Therefore, sequencing results might 
be misleading in heterozygous situations if only one of two different alleles can be 
analyzed. Generally, it can not be excluded that allelic losses occur during the gDNA 
amplification. Therefore, it is inevitable necessary to define the rate of amplification- 
associated allelic losses. Since no own experiments have been performed on this, we 
refer to the work of Schardt, et al. 
166
 who reported a rate of allelic losses due to 
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technical issues of 9.8 % in their control. Although the processing of blood samples 
with the CellSearch
TM
 system differs from the methods that Schardt and colleagues 
have used, we expect a comparable rate of allelic losses because the same amplification 
protocol has been applied. The global amplification of gDNA may have caused allelic 
losses that left heterozygous Kras or BRAF mutations in CTCs unrecognized. However, 
the disparity between the detected mutations in CTCs and corresponding tissue cannot 
be explained exclusively by technical reasons. We believe that the disparity probably 
results from the use of marco-dissections to analyze the malignant tissue. Despite a 
presumptive monoclonal origin tumors are heterogeneous and consist of various 
subpopulations 
106
. Minor subclones that harbor only the wild-type alleles might remain 
unrecognized when thousands of cells were pooled for analysis. In addition, it is 
conceivable that specific genetic changes might have supported tumor cell 
dissemination. For instance, the loss of genes involved in adherence or the 
amplification of genes related to invasiveness would probably favor the dissemination 
process. To our knowledge there are no comparable studies about genomic 
heterogeneity in CRC associated-CTCs. Most studies analyze genetic disparity between 
primary tumors and various sites of metastases. Findings indicate, despite considerable 
inter-study variations, disparate point mutations for Kras in 0-60% 
98, 167-169
 
170
 and for 
TP53 in 20-60% 
171, 172
 of cases. There are a few studies describing genetics of DTCs in 
bone marrow 
97, 173-175
. The frequently observed genomic disparity in DTCs in 
particular in early stages of cancer, they observed, is often explained with postulated 
early tumor cell dissemination 
99
. Tumor cell diversity is still large in early stages since 
genomic instability will lead to the development of various subclones. Once the tumor 
reaches full malignancy the most aggressive clone will prevail. An early dissemination 
and the subsequent parallel progression of DTCs, which further contributes to the 
divergent development, might explain the detected genomic disparity. However, it is 
believed that CTCs can not survive for long time in the circulation. Shear stress 
43
, 
anoikis 
44
 and the easy access of the immune system 
176
 are thought to be the main 
reasons for the short persistence of CTCs in the blood. The high number of genetic 
disparity between CTCs and tumor tissue, that we have detected, is fairly surprising and 
in contrast to a study from Khan et al. 
177
. They studied TP53 mutations in primary 
tumors, liver metastases and CTCs enriched by magnetic beads out of blood samples 
from CRC patients. They reported that if a TP53 mutation was detected it was found 
invariably in all tumor and liver metastasis samples from a single patient and in eight of 
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19 cases it was found additionally in the CTC sample. However, their method could not 
determine if TP53 wild-type tumor cells were also present in the enriched CTC fraction 
or in TP53 mutated carcinomas since they approach did not allow single cell analysis. 
Our CTC isolation protocol provides the opportunity to analyze single CTCs without 
any leukocyte carryover and is, thus, well-suited for CTC- genotyping. CTCs can be 
obtained repeatedly and relatively noninvasive from blood samples, therefore, 
information about their genomic profile might contribute to treatment decision and the 
estimation of prognosis. For instance, information about the mutational status of Kras 
might be crucial for individual therapeutic intervention. The failure of anti-EGFR based 
therapies was reported for colorectal tumors harboring mutant Kras 
152
 or Braf 
153
. We 
were able to show that the mutational status of Kras and BRAF can differ among CTCs 
and matched cancer tissue. Cancer cells might have disseminated at an early point in 
time and have developed in parallel to the tumors they have derived from. Therefore, 
we conclude that genomic analysis of single cancer tissue specimens will not be 
sufficient to state about the genomic profile of systemic cancer. Moreover, it is even 
conceivable that genotypic changes of CTCs might occur during cancer progression. 
This was shown by Meng and colleagues 
178
. They observed in nine of 24 breast cancer 
patients an acquired Her-2 gene amplification in CTCs although the primary tumor was 
initially Her-2 negative. Conversely, the emerge of Her-2 negative CTCs in Her-2 
positive breast cancers subjected to anti-Her-2 therapy was reported by Hayes and 
collegues 
179
.  
In conclusion, here, we describe that the comprehensive genomic characterization of 
single CRC-associated CTCs is feasible. Cancer tissue biopsies consist of an average of 
malignant and non-malignant cells of a tumor and usually neglect individual cancer 
subclones. However, since tumors might consist of heterogeneous cancer cells, the 
single cell analysis could be favorable. We showed that point mutations, MSI and 
chromosomal aberrations that might be important for prediction of survival and therapy 
response can be evaluated in single cells. In addition, the identification of genotypes 
that could be associated with tumor cell dissemination and ectopic survival might open 
new opportunities to develop effective treatments. 
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An orthotopic mouse model of cancer cell dissemination 
 
CTCs are extremely rare and difficult to detect in blood samples of CRC patients. To 
mimic metastatic spread, we have established an orthotopic mouse model of cancer cell 
dissemination in NOD/SCID/gamma mice. Our CRC model comprises all relevant 
steps of metastasis including lymphogenic and hematogenic tumor cell dissemination 
and the successful formation of metastases in liver and lungs. It was possible to isolate 
CTCs from cardiac blood and tumor cells from the ascites of some animals. CTCs were 
viable and could be cultured and expanded in vitro. Moreover, subcutaneous injection 
of CTC-derived cells confirmed their tumorigenicity.  
Clearly lesser CTCs were detected in the cardiac blood in our CRC model than reported 
for othotopic xenograft models of breast 
180
and prostate 
181
 cancer. Most murine models 
determine CTC numbers in blood obtained from heart puncture. In case of an 
orthotopic colon cancer model the venous blood that leaves the tumor needs to pass the 
liver before it reaches the heart 
50
. However, most of the draining blood of prostate or 
mamma carcinomas is drained via the vena cava without having to pass another organ 
which may act as a filter for CTCs. The detection of lower CTC numbers in our CRC 
model confirms the strong filter effect of the liver that we have already postulated in 
the human setting. Moreover, metastases seem to significantly contribute to overall 
cancer cell dissemination since no CTCs were detected before liver metastases have 
formed. We did not find any correlation of the tumor size to the CTC number in the 
xenograft model. Although this is in line with previous findings 
180, 181
, the presented 
cancer model does not allow for the accurate determination of tumor burden throughout 
the animal. Micrometastases might have established at unknown sites distributed all 
over the body. Applying constantly marked tumor cell lines would be desirable for 
further studies. Cancer cell lines with intrinsic GFP or Luciferase expression might 
facilitate an exact tumor and metastasis quantification and might enable an unbiased 
CTC count that does not depend on the expression of epithelial genes. 
Most of the studied genes were found to be similarly expressed in CTCs and solid 
tumor samples. This is in accordance with a previous report about CTCs in an othotopic 
prostate cancer model 
181
. We share the opinion of Helzer and Barnes that the 
biological features necessary for metastatic spread might be already inherent in the 
aggressive cell lines used in both models. This might explain the limited number of 
differentially regulated genes that were detected. Interestingly, Howard and 
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colleagues 
182
 established a CTC cell line from the same orthotopic PC-3 prostate 
cancer model. They report a down-regulation of cell adhesion molecules including E-
cadherin in the CTC-derived cell line. Although, not statistically significant, a clear 
trend for the down-regulation of E-cadherin in CTCs was also observed in our study. 
Together with similar findings in human CTC samples E-cadherin down-regulation 
might be crucial for tumor cell detachment and migration. 
Addressing the question whether EMT is involved in tumor cell dissemination we 
studied the expression of EMT-related transcription factors. Although a tendency for a 
slight up-regulation of Snail was observed in CTC samples, we did not find convincing 
evidence that EMT is critically related to the process of tumor cell dissemination in the 
present mouse model. E-cadherin down-regulation in CTCs might be achieved through 
other mechanisms than EMT and since no up-regulation of mesenchymal genes was 
detected, the contribution of mesenchymal transition to tumor cell dissemination in this 
model remains uncertain. Interestingly, a tendency for the down-regulation of EGFR 
was found in CTCs of the mouse model. Abolished expression of EGFR was also seen 
in the DTCs from human patients. This is in contrast to a study by Wang et al. 
183
. They 
report the mutual regulation of E-cadherin and EGFR. Loss of E-cadherin was found to 
up-regulate EGFR expression and enhanced the proliferation of squamous cell 
carcinoma of the head and neck in cell culture experiments. However, the influence of 
the microenvironment and the loss of close cell-cell contacts after tumor cell 
dissemination might additionally affect EGFR expression. Further studies are required 
to elucidate transcriptional regulation of EGFR during the dissemination process.  
CTC survival and persistence in the circulation may require cellular strategies to 
develop resistance to apoptosis and anoikis. The up-regulation of the anti-apoptotic 
Bcl-2 protein in CTCs has been already reported in a previous study 
181
. We were able 
to show a significant increase in the expression of Survivin, an inhibitor of apoptosis, in 
CTC specimens. Although p53 and β-catenin are linked to Survivin regulation, the 
expression of these genes does not seem to be differentially regulated in CTCs 
compared to solid tumor tissue. The involved regulatory pathways remain therefore 
elusive. Of the metastasis-associated genes included in the present study, we found 
CD44, a hyaluronic acid receptor, up-regulated in CTCs. Hyaluronic acid is the major 
component of the extracellular matrix and over-expression of CD44 in CTCs might be 
involved in homing of CTCs to distant organs 
184
. However, increased expression was 
only seen for the standard isoform CD44s. The transcription level of the putatively 
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metastasis-associated extended isoform CD44v6 seemed not to be altered. Kuhn et 
al. 
130
 postulated that a complex of CD44v6, CO-029, CLDN7 and EpCAM contributes 
to metastasis formation. According to our results which do not indicate the differential 
expression of these genes in our experiments, a correlation could not be confirmed. 
This, however, might be attributed to the used HCT116-P cells, that generally do not 
seem to express the tetraspanin CO-029 which might be important for complex 
formation. Further studies with other cell lines might be useful to assess the role of the 
CD44v6/CO-029/CLDN7/EpCAM complex in tumor cell dissemination.   
 
Conclusion and outlook 
 
In conclusion, our approaches provide the opportunity to characterize CTCs and DTCs 
on the molecular level. We showed that the molecular profiles of CTCs and DTCs are 
not necessarily the same than in the primary tumor or the site of metastasis. Therefore, 
genomic analyses of cancer tissue biopsies for treatment decision might not be 
sufficient for systemic cancer therapy. Moreover, analyzed CTCs appeared to be very 
heterogeneous in general. Therefore, we believe that various subpopulations of CTCs 
exist and only a minority is able to induce metastatic growth. However, until today the 
metastasis-initiating capacity of human CTCs has never been proofed under 
experimental conditions. Neither the molecular traits nor the appropriate culturing 
conditions that could define the true metastatic precursors have been revealed so far. To 
obtain better insights into the biology of metastasis and the resistance to established 
therapies extended studies on CTCs/DTCs are required. Single cell research provides 
the means to gain comprehensive knowledge about individual cancer cell 
heterogeneity. Moreover, the direct characterization of single CTCs/DTCs may allow 
the identification of novel therapeutic targets to defeat systemic cancer disease and may 
elucidate the role of cancer stem cells in metastasis formation. 
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Material and methods 
Methods 
 
Blood samples 
Peripheral blood samples were drawn from healthy donors from the antecubital vein 
and collected in EDTA tubes. To avoid epithelial cell contamination from skin 
puncture, the first 3 ml of blood were discarded. Patients’ blood samples, from patients 
undergoing surgical therapy at the Department of surgery of the University Hospital 
Heidelberg, were obtained after induction of general anesthesia through a central 
venous catheter or from portal or liver vein. After collection, blood samples were 
immediately processed. The study was approved by the ethics committee of the 
University Heidelberg. 
 
Bone marrow samples 
Bone marrow samples were obtained after induction of general anesthesia by iliac crest 
biopsy.  
 
Mononuclear cell collection 
Blood samples were layered over 15 ml of LSM 1077 lymphocyte gradient. The 
samples were centrifuged at 4° C for 30 min at 300g without brake. The interphase 
containing the PBMC fraction was collected and spun down for 5 min at 300 g and 
washed once with PBS. 
 
CTC/DTC enrichment and staining 
PBMC were collected from about 27 ml blood and resuspended in 1.5 ml of beads 
buffer (PBS, 2 mM EDTA, 0.1% AB serum). After washing in beads buffer 450 µl 
magnetic beads were added to PBMCs and incubated in an overhead shaker for 20 min 
at 4° C. According to manufacturers instruction leukocyte depletion ought to be 
performed in a larger volume of buffer. Therefore, cell suspension was diluted with 
additional 8 ml of beads buffer before magnetic separation. Finally, the remaining 
supernatant was centrifuged 5 min 300g to obtain the CTC-enriched cell fraction. Pellet 
was resuspended in 150 µl of PBS buffer containing 10% FCS and 50 U/ml penicillin/ 
streptomycin. Per sample 5µl of Alexa-Fluor488-anti-EpCAM antibody was added. 
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After 20 min of incubation on ice the stained CTCs were identified under a 
fluorescence microscope. A similar protocol was applied for the bone marrow samples. 
In brief, bone marrow aspirates were collected according the mononuclear cell 
collection protocol. The further enrichment and staining of cell samples including 
potential DTCs was performed in the same way as described for the PBMC specimens. 
In case of CTC/DTC detection the identified cells were directly picked with the 
micromanipulator into RNA lysis buffer. 
 
Cancer tissue specimens 
Cancer tissue specimens were minced through a 45 µm cell strainer and collected in 
PBS. After centrifugation for 5 min and 300g the cell pellet was resuspended in 150 µl 
of PBS buffer containing 10% FCS and 50 U/ml penicillin/ streptomycin and stained 
for cancer cell identification with 5 µl anti-EpCAM Alexa488 antibody. Single cancer 
cells or small cell clusters were picked with the micromanipulator directly into RNA 
lysis buffer. 
 
CellSearch
TM
 (Veridex) 
7.5 ml of patients’ blood samples, collected in CellSaveTM tubes, were used for CTC 
analysis according to the manufactures instructions. 
 
Flow cytometry 
Cell sorting was performed on FACS Aria II Flow Cytometer (Beckton Dickinson). 
Protein expression analysis by flow cytometry was carried out on FACS Calibur 
(Beckton Dickinson). Data was analyzed by FlowJo or FACS express software. 
 
Immunohistochemistry 
1-2 µm sections of formalin-fixed, paraffin-embedded tissue samples were mounted on 
object slides. After de-waxing in xylol and ethanol, antigen retrieval was achieved by 
incubating in target retrieval solution (Dako # S1699) for 20 min at 95° C. After 
washing in PBS, slides were incubated in methanol containing 0.3% H2O2 followed by 
washing in PBS. Non-specific binging sites were blocked with 20% normal goat serum 
for 1 hour. Slides were incubated with pre-labeled (Solulink All in one HRP 
conjugation kit #A-9002-001) Moc31-HRP antibody (IQ Products) over night. After 
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washing in PBS the immunoreaction was visualized by using ABC Pro Vecta Stain kit 
(Dako) according to the manual.  
 
Cell culture 
Cells were cultured at 37° C, 5% CO2 and 95% humidity in RPMI supplemented with 
10% FCS, 50 U/ml penicillin and 50 U/ml streptomycin in culture flasks. Cells were 
collected with trypsin EDTA and centrifugation for 5 min at 300 g. 
 
RNA extraction 
Total RNA was extracted by PicoPure RNA isolation kit (Arcturus) according to the 
manual.   
 
RNA amplification 
Amplification of total RNA was achieved by the use of WT Ovation RNA 
amplification kit (NuGen).  
 
RT-PCR 
Real time PCR using SYBR green was performed with LightCycler
TM
 (Roche) 
according to the manual. An annealing temperature of 60° C and 55 cycles of 
amplification were used. Amplification plots were analyzed using the second derivative 
maximum method. All Primers were designed with Primer3Plus software and span 
large intronic regions to exclude amplification of genomic DNA.  
 
gDNA amplification of single cells 
Single cells were transferred into PCR tubes containing 9µl of PBS. 1µl of 
Proteinase K mix (1x OnePhorAll Buffer (OPA), 0.65% Tween, 0.65% Igepal, 1.3 
mg/ml Proteinase K) was added. Cells were digested for 10 h at 42° C in a 
thermocycler followed by an inactivation step of 10 min, 80° C. For MseI digestion 
0.4µl of MseI enzyme (high concentration 10.000 U/ml) was added. After an 
incubation time of 3 h at 37° C the enzyme was inactivated by heating the reaction mix 
to 65° C for 5 min. LIB1 (LIB1: AGTGGGATTCCTGCTGTCAGT) and ddMse11 
(ddMSE11: TAACTGACAGCdd) primers were annealed in a reaction mix of 5µl 10x 
OPA , 5µl LIB1 100µM, 5µl ddMse11 100µM, 15µl H2O in a water bath. For ligation 
6µl of pre-annealed adapters combined with 2µl of 10mM ATP together with 2µl T4 
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DNA ligase were added to the digested cell. Ligation occurred over night at 15° C. 
Genomic DNA was amplified with the help of the Expand long template PCR system 
(Roche) in buffer 1. Therefore, 3µl Buffer 1, 2µl dNTPs 10µM, 25µl H2O and 1µl 
DNA-polymerase mix were combined and added to the reaction mix. Amplification 
was performed in a thermocycler under the following conditions.  
 
cycles 1x 14x 8x 22x 1x 
program 68°C 3min 94° C 40 s 64° C 40 s 94° C 40 s 68° C 220 s 
 57° C 30 s 57° C 30 s + 
1° 
C/cycle 
65° C 30 s 4° C ∞ 
68° C 90s +  
1 s/Cycle 
68° C 150 s +  
1 
s/Cycle 
68° C 113 s + 
1 
s/Cycle 
 
 
For quality control of gDNA amplification a multiplex PCR was used. Therefore 0.3µl 
template was combined with 5µl Dream Taq Green PCR Mastermix (Fermentas), 1µl 
of 10 x primer mix (see table below) and 3.7 µl H2O. PCR was run in thermocycler 
(pre-incubation 2 min 95° C; 33 x amplification 30 s 95° C / 40 s 60° C / 60 s 72° C; 
final elongation 5 min 72° C). Successful amplification was assessed on an agarose gel.  
 
10x Primer mix: 
 
 
Gel electrophoresis of DNA using agarose gels 
PCR products were verified for correct size by electrophoresis at RT using 1.5 % (w/v) 
agarose gels suspended in 1x TAE buffer. GelRed was used in the agarose gel to 
visualize the DNA under UV light. 
 
Primer final conc. PCR Product 
LAMC1 for 0.2 µM 111 bp 
LAMC1 rev 0.2 µM 
GRIK5 for 0.1 µM 232 bp 
GRIK5 rev 0.1 µM 
NRK9 for 0.1 µM 288 bp 
NEK9 rev 0.1 µM 
CAPS for 0.08 µM 175 bp 
CAPS rev 0.08 µM 
PICK1 for 0.08 µM 358 bp 
PICK1 rev 0.08 µM 
DNAH9 for 0.08 µM 401 bp 
DNAH9 rev 0.08 µM 
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Purification of PCR products 
PCR clean up kit (Sigma) was used for purification of PCR products that were used for 
down stream applications such as sequencing, MSI analysis or CGH.  
 
Sequencing 
PCR products that were used for sequence analysis were generated by AmpliTaq Gold 
DNA Polymerase (Applied Biosystems). DNA was sequenced through sequencing 
laboratory (GATC / Konstanz). 
 
Macrodissection and DNA extraction 
For the macro-dissection procedure fresh frozen cancer tissue samples were used. 
Sections of 10µm were cut in a cryostat at -20° C and adhered to object slides. One 
section of each macrodissected sample was hematoxylin / eosin stained and examined 
by light microscopy to discriminate cancer tissue from stroma and healthy tissue. 
Between ten and 20 sections, depending on the amount of cancer tissue, were collected 
for gDNA extraction with the help of Qiagen DNeasy tissue kit according to 
manufacturers instructions. The estimated amount of cancer tissue within the dissected 
area was in every case at least 70 %.  
 
Comparative genomic hybridization (CGH) 
Array-CGH was performed externally by the group of Prof. Dr. N. Stöcklein at the 
University clinic Düsseldorf. For single cell analysis Agilent SurePrint G3 Human 
CGH 4x180K Oligo Microarray Kit (Cat. G4449A) was used. Amplified gDNA of 
single CTCs and matched leukocytes was hybridized against each other. Array-CGH 
analysis of macro-dissected snap frozen cancer tissue probed against matched healthy 
tissue was carried out with Agilent SurePrint G3 Human CGH 8x60K, Oligo 
Microarray Kit (Cat.: G4450A). Data processing was performed with the following 
software provided by Agilent Technologies: Scan Control V 7.0.3; Feature Extraction 
V 10.1.1.1 and Genomic Workbench V 5.0.14. The following parameters were used for 
data analysis:  
Genome build: hg18;  
Evaluation algorithm ADM-2, threshold 6; 
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Aberration filter: minimal number of probes in area 3, minimal mean log 2 ratio for 
area 0.25    
 
MSI 
Analyses of microsatellite instability were performed externally by the group of Dr. M. 
Kloor in the department of pathology at the University Hospital Heidelberg. Amplified 
gDNA of CTC samples as well as tumor samples were tested for MSI in NR21, NR24 
and BAT 25 from the standard NCI/ICG-HNPCC marker panel 
185
 and analyzed as 
described previously 
186
.Genome amplification of CTC-derived gDNA led to disruption 
of the DNA while the afore mentioned markers remained unaffected and were selected 
for MSI analysis. 
 
Mice 
For experiments BalbC nu/nu and NOD/SCID gamma mice were used. Authorization 
number 35-9185.81/G-7/10 was obtained from the national authorities for research 
experiments on animals. Mice were kept under specific pathogen free conditions in IBF 
animal facility Heidelberg. 
 
Orthotopic injection of tumor cells 
Mice were anesthetized by 3-5% of isofluran. A small abdominal incision was made 
and the cecum was exteriorized. 10 
5
 tumor cells in a total volume of 20µl of Matigel 
(10mg/ml) were injected orthotopically into the coecal wall by microinjection. 
Incisions were closed with 6.0 resorbable sutures. For postoperative pain relief 4mg/kg 
Rimadyl was given subcutaneously. 
 
Statistical evaluation 
To identify independent factors associated with detection of CTCs in the CVBC and 
MVBC the following statistical tests were applied. Categorical data were presented as 
absolute and relative frequencies and compared using the χ2-test. Continuous data were 
presented as median and range and compared using the Wilcoxon test. Furthermore, the 
mean number of CTCs was reported. Analysis of covariance (ANOVA) was applied to 
compare continuous data of more than two groups.  
The significance of mRNA expression data differences was evaluated with Student’s T-
test. P – values below 0.05 were considered as statistical significant. 
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Material 
 
Equipment 
CellSearch (Veridex) Ortho Clinical Diagnostics 
Centrifuges Heraeus Multifuge 3; Eppendorf Centrifuge 5810R 
Electrophoresis power supply Consort E835 
Electrophoresis units Neolab 
FACS Aria II BD 
FACS Calibur BD 
Hood Heraeus / Herasafe 
Incubator Binder 
Light cycler 480 Roche 
Microinjection system World Precision Instruments 
Microscopes Leica 
Nanodrop Peqlab 
PCR Thermocycler System Eppendorf 
pipettes Gilson 
Shakers Assitent RM5 
Thermomixer Eppendorf 
Transferman Micromanipulator Eppendorf 
UV- transilluminator BioDoc-It System 
Vortex Scientific industries Vortex Genie 2 
 
Chemicals and reagents 
Agarose  Invitrogen 
Antigen retrieval solution Dako 
ATP NEB 
Deoxyribonucleotide triphosphates (dNTPs) NEB 
Dimethylsulfoxide (DMSO) Sigma 
DMEM PAA 
DNA ladder Fermentas 
DNA loading dye Fermentas 
DynaBeads Dynal / Invitrogen 
EDTA Roth 
Ethanol Roth 
Fetal Calf Serum (FCS) PAA 
Gel red DNA stain Biotium 
H2O2 (30%) Roth 
Igepal-CA630 Sigma 
Isofluran CP Pharma 
LSM 1077 lymphocyte PAA 
Matrigel BD 
Normal goat serum Vector 
Paraformaldehyde Roth 
PBS PAA 
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Penicillin/ Streptomycin PAA 
RPMI PAA 
Trypsin EDTA PAA 
Tween Sigma 
Xylol Roth 
 
Kits 
ABC Vecta Stain kit Dako 
Expand long template PCR system Roche 
LC 480 RT-PCR kit Roche 
PCR clean-up kit Sigma 
Pico Pure RNA extraction  Applied bioscience 
Solu Link All in one HRP conjugation kit Solu link 
WT-Ovation RNA amplification kit Nugen 
 
Enzymes 
AmpliTaq Gold Applied biosystems 
DreamTag Green Fermentas 
MseI Roche 
Proteinase K Roche 
T4 DNA ligase Roche 
 
Antibodies 
Name of antibody Target company 
EpCAM-AlexaFluor 488 EpCAM Biolegend 
CD45-PE CD45 BD 
EpCAM-K/S1-4 EpCAM Santa Cruz 
CD66 CEA BD 
Moc-31 EpCAM IQ-Products 
Ber-Ep4 EpCAM-FITC EpCAM Dako 
Mouse IgG1k Con-FITC Isotype control BD 
EpCAM-VU-1D9 EpCAM ABR 
mouse IgG1-PE isotype control 
 
Isotype control BD 
HEA125 EpCAM Gift of Mollberg 
 
Oligonucleotides 
All used oligonucleotides were obtained from Invitrogen. 
 
Target Name sequence Purpose 
Ascl2 ASCL2_1220F GAGGGGAGAGGATTTTCTAAGG RT-PCR 
Ascl2 ASCL2_1220R TTATTACGCCCCAGGTCAAG RT-PCR 
Bax Bax-Fwd TCTGACGGCAACTTCAACTG RT-PCR 
Bax Bax-Rev GGAGGAAGTCCAATGTCCAG RT-PCR 
B-Catenin Bcat_2344F TTCCGAATGTCTGAGGACAAG RT-PCR 
B-Catenin Bcat_2344R TGGGCACCAATATCAAGTCC RT-PCR 
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Bmi1 Bmi1_1209Fwd GATACTTACGATGCCCAGCAG RT-PCR 
Bmi1 Bmi-1_1209Rev GAAGTGGACCATTCCTTCTCC RT-PCR 
Calreticulin Calr_1040F CCACCCAGAAATTGACAACC RT-PCR 
Calreticulin Calr_1040R TGTCAAAGATGGTGCCAGAC RT-PCR 
CD133 CD133_2410Fa AAAGTGGCATCGTGCAAAC RT-PCR 
CD133 CD133_2410Ra CCGAATCCATTCGACGATAG RT-PCR 
CD151 CD151_759Fwd AGCAACAACTCACAGGACTGG RT-PCR 
CD151 CD151_759Rev TGCTCCTGGATGAAGGTCTC RT-PCR 
CD166 ALCAM3650Fwd GAACACTGCACAGCGATTTC RT-PCR 
CD166 ALCAM3650Rev CAAACACCAGTTTTCCTTTTCC RT-PCR 
CD26 CD26Fwd_2670 AGTCAGCTCAGATCTCCAAAGC RT-PCR 
CD26 CD26Rev_2670 TGTGCTGTGCTGCTAGCTATTC RT-PCR 
CD44s CD44s_Fa AAAGGAGCAGCACTTCAGGA RT-PCR 
CD44s CD44s Ra TGTGTCTTGGTCTCTGGTAGC RT-PCR 
CD44v6 CD44v6_Fb2 GTACAACGGAAGAAACAGCTACC RT-PCR 
CD44v6 CD44v6_Rb2 TGTTGTCGAATGGGAGTCTTC RT-PCR 
CD45 CD45_3819Fb TCTCTTAGAAAGTGCGGAAACAG RT-PCR 
CD45 CD45_3819Rb TCCATTCTGAGCAGGGTAGG RT-PCR 
CD47 CD47_1057F ATAGCCTATATCCTCGCTGTGG RT-PCR 
CD47 CD47-1057R CGGAGTCCATCACTTCACTTC RT-PCR 
CEA CEA5 Fwd_2267 CATGATTGGAGTGCTGGTTG RT-PCR 
CEA CEA5 Rev_2267 TAGGATGGTCTCGATCTCTGG RT-PCR 
CK18 CK18_1288Fwd CCCTGCTGAACATCAAGGTC RT-PCR 
CK18 CK18_1288Rev TCAGACACCACTTTGCCATC RT-PCR 
CK19 CK19TN_Fwd563 GCGAGCTAGAGGTGAAGATCC RT-PCR 
CK19 CK19TN_Rev563 TGTCGATCTGCAGGACAATC RT-PCR 
CK20 CK20 1219 Fa ACGCCAGAACAACGAATACC RT-PCR 
CK20 CK20_1219 Ra GCCATCCACTACTTCTTGCAC RT-PCR 
CLDN7 CLDN7_656Fa TGAGCTGCAAAATGTACGACTC RT-PCR 
CLDN7 CLDN7_656 Ra CACAAACATGGCCAGGAAG RT-PCR 
c-Myc C-myc_1327F TGCTCCATGAGGAGACACC RT-PCR 
c-Myc C-myc_1327R GATCCAGACTCTGACCTTTTGC RT-PCR 
CO029 CO-029_444Ra ACAGCTCCTAGGATACCTGTCG RT-PCR 
CO-029 CO-029_444Fa TGATTGCTGTAGGTGCCATC RT-PCR 
CXCR4 CXCR4_1000F CATCATGGTTGGCCTTATCC RT-PCR 
CXCR4 CXCR4_1000R CGATGCTGATCCCAATGTAG RT-PCR 
Cyclin D1 CCND1Fwd_933 TCCTCTCCAGAGTGATCAAGTG RT-PCR 
Cyclin D1 CCND1Rev_933 TTGGGGTCCATGTTCTGC RT-PCR 
DLG7 DLGPA5fwd_2338 TGAAAGCAGGAGCAGCATAG RT-PCR 
DLG7 DLGPA5rev_2338 ATCTGCTACTCCACCAGCAAG RT-PCR 
E-cadherin E-Cad2563F AGAGGACCAGGACTTTGACTTG RT-PCR 
E-cadherin E-Cad2563R TCAGTATCAGCCGCTTTCAG RT-PCR 
EGFR EGFR_3517Fwd TTCTTGCAGCGATACAGCTC RT-PCR 
EGFR EGFR_3517Rev TGGGAACGGACTGGTTTATG RT-PCR 
EGR1 EGR1_577F CAGCACCTTCAACCCTCAG RT-PCR 
EGR1 EGR1_577R AGCGGCCAGTATAGGTGATG RT-PCR 
EpCAM EpCAM_733Fa CTGGATCCAAAATTTATCACGAG RT-PCR 
EpCAM EpCAM_733Ra GTTCCCCATTTACTGTCAGGTC RT-PCR 
HDAC1 HDAC1_1042Fwd TTAACCTGCCTATGCTGATGC RT-PCR 
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HDAC1 HDAC1-1042Rev GAAGGACTGATGTGGAGCTTG RT-PCR 
HDAC3 HDAC3_1283Fwd ACAGGACTGATGAGGCTGATG RT-PCR 
HDAC3 HDAC3_1283Rev CCCAACCAAGAGGTGAAAAG RT-PCR 
hFN hFN1 CAGTGGGAGACCTCGAGAAG RT-PCR 
hFN hFN1 TCCCTCGGAACATCAGAAAC RT-PCR 
Ki67 Ki67_8625Fwd ACAAAAGGTGCTTGAGGTCTG RT-PCR 
Ki67 Ki67_8625Rev CCTTTCCCTTTCTGATTCTGC RT-PCR 
Lgr5 LGR5_1685F TCATTCAGTGCAGTGTTCACC RT-PCR 
Lgr5 LGR5_1685R CTGCGATGACCCCAATTAAC RT-PCR 
Maspin SerpinB5Fwd_877 ACACCAAACCAGTGCAGATG RT-PCR 
Maspin SerpinB5Rev_877 CTGTGACAGTGACTCTGAGTTGAG RT-PCR 
MMP7 MMP7Fwd_822 TTGGGTATGGGACATTCCTC RT-PCR 
MMP7 MMP7Rev_822 GAATGGATGTTCTGCCTGAAG RT-PCR 
MRP2 MRP2_4453Fwd AGCCTGCAACTTGGGTTATC RT-PCR 
MRP2 MRP2_4453Rev TGGTCGTCTGAATGAGGTTG RT-PCR 
MRP4 MRP2_2655Fwd CTGCCGCTGACGTTTTTAG RT-PCR 
MRP4 MRP2_2655Fwd AATCCCAGCACTGAGGTTTG RT-PCR 
MRP5 MRP2_453Fwd AGATGCCTTGGAAACAGCAG RT-PCR 
MRP5 MRP2_453Fwd AAAAAGCCCAGCATTGTCC RT-PCR 
Musashi Msi1Fwd_1174 CTTTGATTGCCACAGCCTTC RT-PCR 
Musashi MsiRev_1174 GCTGGCTCACTCGTGGTC RT-PCR 
N-cadherin N-Cad2973Fneu GAATGGATGAAAGACCCATCC RT-PCR 
N-cadherin N-Cad2973R AGTCATATGGTGGAGCTGTGG RT-PCR 
Olfactomedin 4 Olfm4_730Fa AGATCAAAACACCCCTGTCG RT-PCR 
Olfactomedin 4 Olfm4_730Ra GAAAACCCTCTCCAGTTGAGC RT-PCR 
P21 p21Fwd_571 ATGTGGACCTGTCACTGTCTTG RT-PCR 
P21 p21Rev_571 GGATTAGGGCTTCCTCTTGG RT-PCR 
Snail1 SnailR_680 TCTTGACATCTGAGTGGGTCTG RT-PCR 
Snail1 SnailFb_680 TCTAGGCCCTGGCTGCTAC RT-PCR 
Survivin Birc5Fwd_232 TTTTCATCGTCGTCCCTAGC RT-PCR 
Survivin Birc5Rev_232 AGCCCGGATGATACAAACAG RT-PCR 
TP53 p53Fwd_1297 TGAATGAGGCCTTGGAACTC RT-PCR 
TP53 P53Rev_1297 TTTTATGGCGGGAGGTAGAC RT-PCR 
Twist1 Twi1100Fb GGGCCGGAGACCTAGATG RT-PCR 
Twist1 Twi1100R CCACGCCCTGTTTCTTTG RT-PCR 
Vimentin Vim1483F TTTTCCTCCCTGAACCTGAG RT-PCR 
Vimentin Vim1483R CGTGATGCTGAGAAGTTTCG RT-PCR 
ZEB1 ZEB1_2664Fwd CTAGCTGCCAATAAGCAAACG RT-PCR 
ZEB1 ZEB1_2664Rev TTGGGCGGTGTAGAATCAG RT-PCR 
Β-Actin b-Act_1404Fa ATGTGGCCGAGGACTTTGATT RT-PCR 
Β-Actin b-Act_1510Ra AGTGGGGTGGCTTTTAGGATG RT-PCR 
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Preamplification 
 
P53E5/6 E5/6Fwdx TTCACTTGTGCCCTGACTTTCAAC Tissue 
P53E5/6 E5/6Revx GCCACTGACAACCACCCTTAAC Tissue 
P53E7 E789seqP53Fwd CCTCATCTTGGGCCTGTGTTATC Tissue 
P53E7 E7 Revx TGGAAGAAATCGGTAAGAGGTGG Tissue 
P53E8 E8Fwdx GGACCTGATTTCCTTACTGCCTC Tissue 
P53E8 E8Revx CTGAGGCATAACTGCACCCTTG Tissue 
BRAF BRAF_Fwd GTGGGATTCCTGCTGTCAGTTAAAG CTC 
BRAF BRAF-Rev AGCCTCAATTCTTACCATCCAC  CTC 
Kras KrasFwd TCCTGCTGTCAGTTAACCTTATG CTC 
Kras KrasRev CTGTCAGTTAAAACAAGATTTACC CTC 
P53E5/6 P53Exon5/6Fwd GCTGTCAGTTAATGTGTGATCTC CTC 
P53E5/6 P53 Exon5/6Rev GTCAGTTAACCCCTCCTCCCAG CTC 
P53E7 P53E7Fwd GCAGTGGCTCATGCCTGTAATC CTC 
P53E7 P53E7Rev GAGTGGGAGCAGTAAGGAGA CTC 
P53E8 P53E8_Fwd GGGATTCCTGCTGTCAGTTAAATGG CTC 
P53E8 P53E8 _Rev CATTGTCTTTGAGGCATC CTC 
 
Sequencing 
 
Target Name sequence Purpose 
BRAF  BRAF fwd CTCTTCATAATGCTTGCTC CTC + Tissue 
BRAF  BRAF rev CCATCCACAAAATGGATCC CTC + Tissue 
Kras Kras Fwd TCCTGCTGTCAGTTAACC CTC 
Kras Kras Rev1 ACCTCTATTGTTGGATC CTC 
P53E5/6 p53E5/E6Fwd GTGATCTCTGACTCCTGTC CTC 
P53E5/6 p53 rev1 AGAGACCCCAGTTGCAAAC CTC 
P53 E7 p53E7rev GGGAGCAGTAAGGAGATTC CTC 
P53 E8 p53E8-Fwd AAATGGGACAGGTAGGAC CTC 
P53 E8 p53E8-Rev CATTGTCTTTGAGGCATC CTC 
P53E5 E5p53gDNAFwd TTCACTTGTGCCCTGAC Tissue 
P53E5 E5p53gDNARev ACTGACAACCACCCTTAAC Tissue 
P53E7 E7p53gDNAFwd ATCTTGGGCCTGTGTTATC Tissue 
P53E7 E7p53gDNARev TGGAAGAAATCGGTAAGAG Tissue 
P53E8 E8p53gDNaFwd GGACCTGATTTCCTTACTG Tissue 
P53E8 E8p53gDNARev CTGAGGCATAACTGCAC Tissue 
Kras KrasFwd AAGGCCTGCTGAAAATGACTG Tissue 
Kras KrasRev AGAATGGTCCTGCACCAGTAA Tissue 
 
MSI Analysis 
 
Target Name sequence Purpose 
NR21 NR-21_fwd TAAATGTATGTCTCCCCTGG MSI analysis 
NR21 NR-21_rev ATTCCTACTCCGCATTCACAA MSI analysis 
NR24 NR-24_fwd CCATTGCTGAATTTTACCTC MSI analysis 
NR24 NR-24_rev ATTGTGCCATTGCATTCCAAA MSI analysis 
BAT25 Bat25F TCGCCTCCAAGAATGTAAGT MSI analysis 
BAT25 Bat25R TATGGCTCTAAAATGCTCTGTTC MSI analysis 
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Multiplex Primer quality control CTC amplification 
 
LAMC1For TCTGCTTTGGGCATTCTTCT 
LAMC1Rev TTCTAACAGGTTGGGGGATG  
CADPSFor  CCCCACCCTTCTTCACTACA 
CADPSRev  GTGTGCACATACCACCGAAG 
GRIK5For  CTAGCTCCCACCAACCTCAG 
GRIKRev CTCGATGATCCCGTTGATCT 
NEK9For  GCAGGAGGGAACCTGTATGA 
NEK9Rev CAGGAAAGAAAGCCCACAGA 
PICK1For TCGTATGCTGGAGTCCTGTG 
PICK1Rev GGGATGGCTTTGTTGAGGTA 
DNAH9For GGGTCTCATCACCAGCATTT 
DNAH9Rev  GCCATCTTCCACATGGTCTT 
 
 
Cell lines 
Cell lines were obtained from DSMZ and their identity is regularly confirmed. 
- HCT116 
- HT29 
- SW480 
- DLD1 
- Colo205 
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Supplementary figure 1: Genomic analyses of CTCs. MSS= microsatellite stable; MSI=microsatellite instablity; wt =wild type; mutations are indicated in red; number in 
brackets indicate the number of analyzed cells 
 
 MSS / MSI Kras Braf TP53 Exon 5/6 TP53 Exon 7 TP53 Exon8 
Patient ID CTC tissue CTC tissue CTC tissue CTC tissue CTC tissue CTC tissue 
HD1960 MSS (1) MSS X wt wt (1) wt X wt X wt X wt 
HD2026 MSS (1) MSS X wt wt (1) wt wt (1) wt wt (1) wt X FS_C184 
HD2030 MSS (5) X wt (8) wt wt (4) wt wt (5) wt wt (7) wt wt (6) wt 
HD2050 MSS (1) X wt (1) X wt (1) X wt (1) X wt (1) X wt (1) X 
HD2054 MSS (3) MSS wt (2) wt 
V600E(1)/ 
wt(1) 
V600E wt (2) wt wt (2) wt wt (2) wt 
HD2068 MSS (2) MSS wt (1) wt X wt R175H (2) R175H wt (1) wt wt (1) wt 
HD2077 MSS (1) MSS wt (1) wt X wt wt (1) wt wt (1) wt wt (1) wt 
HD2078 MSS (1) MSS wt (1) wt wt (1) wt wt (1) wt X X wt (1) X 
HD2091 MSS (1) MSS wt (1) wt X wt wt (1) wt wt (1) wt R273C (1) R273C 
HD2094 MSS (1) MSS X wt Wt wt wt (1) X wt (1) X wt (1) X 
HD2095 MSS (13) X wt (8) G12D wt (1) wt wt (9) wt wt (9) wt wt (7) wt 
HD2101 MSS (1) MSS wt (1) G12D X wt wt (1) wt wt (1) wt wt (1) wt 
HD2113 MSS (4) MSS wt (1) wt wt (2) wt wt (2) wt wt (4) wt R282W (4) R282W 
HD2126 MSS (1) MSS X G12D wt (1) wt A159V (1) A159V wt (1) wt wt (1) wt 
HD2131 MSS (1) MSS wt (1) G12V wt (1) wt X wt wt (1) wt wt (1) wt 
HD2165 MSS (14) MSS wt (8L; 5P) wt wt (8) wt wt (13) wt wt (14) wt wt (14) wt 
HD2179 MSS (1) MSS wt (1) wt wt (2) V600E R175H (1) R175H X wt wt (1) wt 
HD2201 MSS (1) MSS G12C (1) G12C X wt R175H (1) R175H X wt wt (2) wt 
HD2202 MSS (1) MSS G13D (1) wt wt (1) wt wt (1) wt wt (1) wt wt (1) wt 
HD2203 MSS (3) X wt (1) X wt (3) wt wt (2) wt wt (2) wt 
EE285, 
286DA(3) 
wt 
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HD2215 
MSS(9)/ 
MSI(2) 
MSS 
G12S(4)/ 
wt (2) 
G12S wt (6) wt wt (2) wt wt (4) wt wt (5) wt 
HD2224 MSS (7) MSS wt (7) G12R wt (6) wt wt (6) wt wt (5) wt wt (7) wt 
HD2231 MSS (4) MSS wt (4) wt wt (4) X wt (4) wt G245S (3) G245S wt (4) wt 
HD2246 MSS (3) X wt (3) xx wt (3) X wt (3) X wt (3) X wt (2) X 
HD2257 X MSS X wt wt (1) X X wt wt (1) R248Q wt (1) wt 
HD2288 MSS (7) MSS 
G12A(4)/ 
wt(2) 
G12A wt (5) wt wt (5) wt wt (6) wt 
R273C(4)/ 
wt(1) 
R273C 
HD2295 MSS (7) MSS wt (7) wt wt (6) V600E wt (7) wt wt (7) wt wt (8) wt 
HD2328 MSS (14) MSS wt (12) wt wt (9) wt 
F134C(3L)+ 
wt(3LV,4M
es) 
F134C_LM; 
wt_Tu? 
wt (10) wt wt (11) wt 
HD2334 MSS (8) MSS 
G12S(7)/ 
wt(1) 
G12S wt (8) X wt (7) X wt (7) wt wt (8) wt 
HD2341 
MSI(2) 
/MSS(1) 
X 
G13D(2)/ 
wt(1) 
X wt (2) X wt (3) X wt (3) X wt (3) X 
HD2351 MSS (1) MSS wt(1) X wt (1) X wt (1) X wt (1) wt wt (1)  
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Supplementary figure 2: Patients characteristics. Patients from whom CTCs and cancer tissue 
specimens were obtained for genomic analyses are listed. f=female, m=male, Tu=tumor, LM=liver 
metastasis, LuMet=lung metastasis, LN=lymph node metastasis, PB peripheral blood, LV= liver vein, 
PV=portal vein  
 
Patient ID Sex Age UICC Stage Analyzed tissue 
CTC obtained 
from 
Detected genomic 
disparity between 
CTCs and cancer 
tissue 
HD1960 f 81 IV Tu PB  
HD2026 M 66 IV LM PB  
HD2030 m 54 IV Tu LV  
HD2050 M 53 I - PV  
HD2054 m 53 III Tu PB  
HD2068 m 36 IV LM+LuMet LV  
HD2077 f 72 I Tu1+Tu2 LV  
HD2078 m 68 IV Tu LV  
HD2091 M 53 IV Tu LV  
HD2094 f 74 IV LM LV  
HD2095 f 69 IV Tu LV x 
HD2101 f 85 III Tu LV x 
HD2113 f 48 IV Tu LV  
HD2126 f 64 IV Tu LV  
HD2131 f 61 IV Tu PB x 
HD2165 m 50 III LM LV+PV  
HD2179 f 60 IV LM PB x 
HD2201 m 65 IV LM LV+PV  
HD2202 m 56 III LN-Met PV x 
HD2203 f 38 IV - PB  
HD2215 f 85 IV LM LV  
HD2224 m 62 III LN-Met LV x 
HD2231 m 63 IV LM LV  
HD2246 m 64 I - LV  
HD2257 f 55 IV LM PB x 
HD2288 F 59 IV LM LV  
HD2295 f 80 III Tu LV x 
HD2328 f 64 IV Tu LV+PV  
HD2334 m 74 III LN-Met PV  
HD2341 m 51 IV - PV  
HD2351 w 83 II Tu PV  
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Supplementary figure 3: Array-CGH profiles of CTCs and cancer tissue samples. The human set of 
chromosomes is shown (1-22, X, Y). Beside each chromosome the detected signal intensity of the array-
CGH analysis is depicted. Amplitudes to the left reflect chromosomal losses. Amplitudes to the right 
reflect chromosomal gains. CTCs were obtained from blood samples as indicated: PB=peripheral or 
central blood, LV=liver vein, PV=portal vein. 
 
 
Matrix-CGH profile HD2026 CTC (PB) 
 
 
 
 
 
Matrix-CGH profile HD2030 CTC (LV) 
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Matrix-CGH profile HD2095 CTC (LV) 
 
 
 
 
 
 
Matrix-CGH profile HD 2126 CTC (LV) 
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Matrix-CGH profile HD 2224 CTC (LV) 
 
 
 
 
 
Matrix-CGH profile HD2231 CTC (LV) 
 
Appendix 
102 
 
 
Matrix-CGH profile HD2288 CTC (LV) 
 
 
 
 
 
Matrix-CGH profile HD2295 CTC (LV)  
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Matrix-CGH profile HD2328 CTC (LV) 
 
 
 
 
 
Matrix-CGH profile HD2334 CTC (PV) 
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Matrix CGH profile of HD2026 liver metastasis tissue 
 
 
 
 
 
Matrix CGH profile of HD2095 liver metastasis tissue 
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Matrix CGH profile of HD2126 liver metastasis tissue 
 
 
 
 
 
Matrix CGH profile of HD2224 tumor tissue 
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Matrix CGH profile of HD2231 liver metastasis tissue 
 
 
 
 
 
Matrix CGH profile of HD2288 liver metastasis tissue 
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Matrix CGH profile of HD2328 liver metastasis tissue 
 
 
 
 
 
Matrix CGH profile of HD2334 tumor tissue 
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